AU784397B2 - Benzo(A)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II - Google Patents

Benzo(A)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II Download PDF

Info

Publication number
AU784397B2
AU784397B2 AU17184/01A AU1718401A AU784397B2 AU 784397 B2 AU784397 B2 AU 784397B2 AU 17184/01 A AU17184/01 A AU 17184/01A AU 1718401 A AU1718401 A AU 1718401A AU 784397 B2 AU784397 B2 AU 784397B2
Authority
AU
Australia
Prior art keywords
benzo
carboxylic acid
ethyl
amide
phenazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU17184/01A
Other versions
AU1718401A (en
Inventor
William Alexander Denny
Adrian John Folkes
John Milton
Nigel Vicker
Shouming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Publication of AU1718401A publication Critical patent/AU1718401A/en
Application granted granted Critical
Publication of AU784397B2 publication Critical patent/AU784397B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

1 PHARMACEUTICAL COMPOUNDS The present invention relates to substituted benzo[a]phenazine- 11-carboxamides and derivatives thereof. These compounds are cytotoxic agents which have demonstrated topoisomerase I and topoisomerase II inhibition and have the ability to circumvent multidrug resistance mechanisms. They are therefore potential anticancer agents The topoisomerases are important cellular targets for a number of successful chemotherapeutic agents (Wang, Ann. Rev. Biochem, 65, 635-692, 1996) and are essential enzymes in the regulation of DNA topology which is required if cells are to divide and proliferate (Wang, loc cit). Drugs that target topoisomerase II, for example doxorubicin and etoposide, have been widely used in cancer chemotherapy (Hande, Biophys. Acta 1400, 173- 184,1998) while those that specifically target topoisomerase I, principally the camptothecin analogues, have made an important impact more recently, an example being CPT-11 for the treatment of colon cancer (Dancey et al, Br. J. Cancer 74, 327-338, 1996). More recently, topoisomerases have been shown to be therapeutic targets for antifungal, antibacterial and antiviral drugs (Chen et al, Rev. Pharmacol. Toxicol, 34, 191-218, 1994).
In addition to those compounds that specifically target topoisomerase I or II, several joint inhibitors of topoisomerase I and II have been identified and may also be beneficial in the treatment of solid tumours. These compounds include intoplicine (Riou et al Cancer Res. 53, 5987-5993, 1993), DACA/XR5000 (Finlay et al, Eur. J. Cancer 32A, 708-714, 1996) and TAS-103 (Utsugi et al, J. Cancer Res, 88, 992-1002 1997) which are all in clinical evaluation. The advantage of joint inhibitors of topoisomerase I and II is their ability to avoid drug resistance and to target two key enzymes that affect the topology of DNA which o: are active at different points in the cell cycle.
It has now been found that a class of novel benzo[a]phenazine-l 1-carboxamides are inhibitors of topoisomerase I and topoisomerase II. Accordingly, the present invention provides a compound which is a benzo[a]phenazine-l 1-carboxamide derivative of formula
(I)
A5S98140speci R 4 N
R
7 R RI O N -N(R 8
)(R
9
H
R2
H
wherein each of R' to R 3 is hydrogen and R 4 is selected from halogen, hydroxyl, Ci-C 6 alkoxy which is unsubstituted or substituted, heteroaryloxy, CI-C 6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO 2
R
1 0
CON(RI
2 2
OCON(R
2 2 SRIO, SOR", S0 2
R
1 1
SO
2 N(RI2) 2 N(RI2) 2 NRIoS0 2
N(SO
2 R")2,
NR'O(CH
2 )nCN, NR'1COR", OCOR" or COR' 0 each of R 5 to R 7 which are the same or different, is selected from hydrogen, halogen, hydroxy, Ci-C 6 alkoxy, CI-C 6 alkyl, SR 0 and N(R' 2 2 Q is Ci-C 6 alkylene which is unsubstituted or substituted by Ci-C 6 alkyl which is S" unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not ct to either of the N atoms adjacent to Q in formula (iii) CO 2 R'O, or (iv) CON(RI2) 2
R
8 and R 9 which are the same or different, are each hydrogen or Ci-C 6 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are attached form a saturated 5- or 6membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R 8 and R 9 is an alkylene chain optionally interrupted by .0 O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; 20 R 1 0 is hydrogen, Ci-C 6 alkyl, C 3 -Cio cycloalkyl, benzyl or phenyl; S* R is CI-C 6 alkyl, C 3 -CIO cycloalkyl, benzyl or phenyl; each R 1 2 which are the same or different, is hydrogen, Ci-C 6 alkyl, cycloalkyl, benzyl or phenyl, or the two R 1 2 groups form, together with the nitrogen atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic ring which may include 1 or 2 additional heteroatoms selected from O, N and S; and n is 1,2 or3; or a pharmaceutically acceptable salt thereof.
AS08140speci In a preferred aspect of the invention the benzo[a]phenazine carboxamide-l1derivative is of formula (Ia)
R
SI (Ia) N R 1 3 3)C S R1 0 (CH2) N(R)(R 9 R 2 1
H
wherein R' to R 9 are as defined above; p is 1, 2 or 3; and
R'
3 is hydrogen (ii) Ci-C 6 alkyl which is unsubstituted or substituted by hydroxy, aryl or
N(RI
2 2 in which R 1 2 is as defined above, (iii) CO 2 R'O, (iv) CON(R 2 2 or aryl.
When one of R 8 and R 9 in formula is an alkylene chain which is attached to a carbon atom on Q, the compound of formula has the following structure (Tb): R 6 (Ib) N R R4 N R 7 3 R'R N-W- H -R14
R
2
H
wherein R' to R 7 are as defined above for formula
R'
4 is hydrogen or Ci-C 6 alkyl; W is a direct bond or a C]-Cs alkylene chain; and Y and Z form, together with the N and C atoms to which they are attached, a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional O, N or S atom.
AS98140speci A CI-C 6 alkyl group may be linear or branched. A CI-C 6 alkyl group is typically a C 1
C
4 alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group. A CI-C 6 alkyl group is unsubstituted or substituted, typically by one or more groups selected from hydroxy-Ci-C 6 alkyl wherein the alkyl moiety is unsubstituted or substituted as specified herein for CI-C 6 alkyl, Ci-C 6 alkoxy, phenyl, N(R' 2 2 wherein R 1 2 is as defined above, and hydroxy. Examples ofhydroxy-Ci-C 6 -alkyl include, for instance, hydroxymethyl, 1-hydroxyethyl and 2-hydroxyethyl. CI-C 6 alkylene is a C 1
-C
6 alkyl group as defined above which is divalent.
An aryl group is typically an aromatic C 6 -Clo carbocyclic group, such as phenyl or naphthyl, which is unsubstituted or substituted by halogen, C 1
-C
6 alkyl, OH, CI-C 6 alkoxy,
NO
2 N(RI2) 2 C0 2
R
1 0 CN or perhalo Ci-C 6 alkyl such as CF 3 A halogen is F, Cl, Br or I. Preferably it is F, Cl or Br.
A CI-C 6 alkoxy group may be linear or branched. It is typically a Ci-C 4 alkoxy group, for example a methoxy, ethoxy, propoxy, i-propoxy, n-propoxy, n-butoxy, sec-butoxy or tertbutoxy group. A CI-C 6 alkoxy group is unsubstituted or substituted, typically by one or more groups selected from N(RI2) 2
CON(R'
2 2 hydroxy, CI-C 6 alkoxy, Ci-C 6 alkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, cyano, C0 2
R'
1
COR
I1 a saturated 5- or 6-membered N-containing heterocyclic group or phenyl, the phenyl group being unsubstituted or substituted by one or more halogen atoms.
20 A C 3 -CIO cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Typically it is C 3
-C
6 cycloalkyl. A C 2
-C
6 alkenyl group contains one or more unsaturated bonds. It may be, for instance, vinyl, propenyl, butenyl or pentenyl. A C 2
-C
6 alkynyl group may be ethynyl, propynyl, butynyl or pentynyl. A saturated 5- or 6-membered N-containing heterocyclic ring may be, for example, piperidine, piperazine, morpholine or :25 pyrrolidine.
S
A heteroaryloxy group is a group -OHet in which Het is an unsaturated 5- or 6- S" membered N-containing heterocyclic ring which may include one or more additional O, N or S atoms. Examples include furan, thiophene, pyrrole, indole, isoindole, pyrazole, imidazole, isoxazole, oxazole, thiazole, isothiazole, pyridine, quinoline, quinoxaline, isoquinoline, thienopyrazine, pyran, pyrimidine, pyridazine, pyrazine, purine and triazine. The aforesaid heterocyclic ring may be unsubstituted or substituted by one or more substituents, for instance one or more substituents selected from OH, halogen, CI-C 6 alkyl which is unsubstituted or substituted, for example by halogen (such as CF 3
CI-C
6 alkoxy, nitro and an amino group N(RI2)2 as defined above.
A598140spcce In compounds of the invention, R' to R 3 in formula (1a) or (lb) are each hydrogen and R 4 is other than hydrogen. Typically R 4 is C 1
-C
6 alkoxy, hydroxy, C 1
-C
6 alkyl, hydroxy- C I-C 6 alkyl, nitri le or halogen.
In a preferred series of compounds R 4 in formnula (Ia) or (1b) is C I-C 6 alkoxy or hydroxy, R 7 is hydroxy, and R1 to R 3 R 5 and R 6 are each hydrogen. Also preferred are compounds wherein R 4 is C 1
-C
6 alkoxy or hydroxy, R 6 is C 1
-C
6 alkoxy, halogen or methylthio and R' to R 3 R 5 and R 7 are all hydrogen.
In formula (1a) R 1 3 is preferably C 1
-C
6 alkyl, more preferably methyl.
In formulae and (1a) a preferred option for Q is a C 2 or C 3 alkylene chain which is substituted (x to the adjacent amide nitrogen atom by C 1
-C
6 alkyl which is unsubstituted or substituted as defined above. Preferably the substituent on Q is unsubstituted C 1
-C
6 alkyl or hydroxy-C 1
-C
6 alkyl such as hydroxymethyl or hydroxyethyl. Typically the C 2 or C 3 alkylene chain is substituted (x to the adjacent amide nitrogen atom by methyl, ethyl, isopropyl, hydroxymethyl, substituted hydroxymethyl or 1-hydroxyethyl.
Examples of preferred compounds of the invention are: Compound Namne Compound Number 4-Methoxy-benzo[a]phenazine- I1I -carboxylic acid 3 dimethylamino-ethyl)-amide 4-Hydroxy-benzo[a]phenazine- II-carboxylic acid 4 dimethylamino-ethyl)-amide: hydrobromide salt 4-Nitro-benzo[a]phenazine- 11I -carboxylic acid 7 dimethylamino-ethyl)-amide 9 -Bromo-4-methoxy-benzo[a]phenazine- I I -carboxylic acid di methylamino-ethyl)-amide 4-Cyanomethoxy-benzo[a]phenazine- 1-carboxylic acid 11 di methylamino-ethyl)-amide 4-Benzyloxy-benzo[a]phenazine- II-carboxylic acid 12 d imethylami no-ethyl)-amide 4 -Prop-2-ynyloxy-benzo[a]phenazine- I1 -carboxyl ic acid 13 -dirnethylamino-ethyl)-amide 4-Ethoxy-benzo[a]phenazine- 11 -carboxylic acid di methylamino-ethyl)-amide 4- lsobutoxy-benzo[a]phenazine-I 1-carboxylic acid 16 dimethylamino-ethyl)-amide 4 4 -Chloro-benzyloxy)-benzo[a]phenazine- 11 -carboxyl ic acid 17 (2-d irethylamino-ethyl)-amide 4-(2-Methoxy-ethoxy)-benzo[a]phenazinel 1-carboxylic acid 18 diniethylaniino-ethyl)-amide 4-(2-1-lydroxy-ethoxy)-benzo[a]phenazine- 11 -carbox yl ic acid 21 diniethylamnino-ethyl)-amide ASQS I Jspc.
4 -(Pyrimidin-2-yloxy)-benzo[a]phenazine-I 11-carboxylic acid 22 dimethylamino-ethyl)-amide 4 2 -Morpholin-4-yl-ethoxy)-benzo[a]phenazine. 11 -carboxyl ic 23 acid (2-dimethylamino-ethyl)-amide 4 3 -Cyano-propoxy)-benzo[a]phenazine- I11 -carboxylic acid 24 dimethylamino-ethyl)-amide 4-Methyl-berizo[a]phenazine- 11I -carboxylic acid(2- dimethylamino-ethyl)-amide 4-Fluoro-benzo[a]phenazine- I I -carboxylic acid(2- 26 di1m ethyl amino-ethyl)-am ide 4 3 -Dimethylamino-propoxy)-benzo[a]phenazine- 11I -carboxylic 27 acid (2-dimethylamino-ethyl)-arnide 4-Methylsul fanyl-benzo[a]phenazine-I 11-carboxylic acid 28 dimethylamino-ethyl)-amide 4-Carbamoylmethoxy-benzo[a]phenazine-1 I1-carboxylic acid 29 dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- I I -carboxylic acid (3-amino-2- hydroxy-propyl)-amide_________ 4 -Methoxy-benzo[a]phenazine- I I -carboxylic acid 31 di1m ethyl amino-propyl)-ami1de 4 -Bromo-benzo[a]phenazine- II-carboxylic acid 32 dimcthylamino-ethyl)-amide Acetic acid I l-(2-dimethylamino-ethylcarbamoyl)- 33 benzo[ajphenazin-4-yl ester 4 2 -Oxo-propoxy)-benzo[a]phenazine 11I -carboxylic acid 34 dimethylamino-ethyl)-amide 4 -Methoxy-benzo[a]phenazine- I 1-carboxylic acid dimethylamino- I -methyl -ethyl) -am ide 4-Cyano-benzo[a]phenazine- I1I -carboxylic acid 36 dimethylamino-ethyl)-amide Ethyl-carbamic acid 11 -(2-dimethylamino-ethylcarbamoyl)- 37 benzo[ajphenazin-4-yl ester 4 -Methanesulfonyl-benzo[a]phenazine-I I -carboxylic acid 39 dirnethylamino-ethyl)-amide 4-Chloro-benzo[a]phenazine- II-carboxylic acid di methylamino-ethyl)-amide 4-Azido-benzo[a]phenazine- 11 -carboxylic acid(2- 41 diniethylaniino-ethyl)-amide 4-Amino-benzo[a]phenazine- 11I -carboxylic acid 42 -di methylamino-ethyl)-amide [I1-(2-Di methylamino-ethylcarbamoyl)ybenzo[ajphenazin-4 43 yloxy]-acetic acid trifluoro-acetate salt 4-Acetylam ino-benzo[a]phenazine- I11 -carboxylic acid 44 diniethylai-ino-ethyl)-amide I I -(2-Dinmethylamino-ethylcarbamoyl)-benzo~ajphenazine-4 carboxylic acid methyl ester 4 -Bis-(Methanesulfonylamino)-benzo[ajphenazine- 11- 46 carboxylic acid (2-dimethylamino-ethyl)-amide 4 -(N-Hydroxycarbamimidoyl)-benzo[a]phenazine-11 -carboxylic 48 A598S Opec.
acid (2-dimethylamino-ethyl)-amid,- 4-Hydroxymethyl-benzo[a]phenazine- I11 -carboxylic acid 49 dimethylamino-ethyl)-amide 11 -D im ethyl am ino-ethylcarbamo yl)-benzo phenazi ne-4- carboxylic acid, trifluoroacetate salt 4-Methylsul famoyl-benzo[a]phenazine- I I -carboxylic acid 51 dimethylamino-ethyl)-amide; trifluoro-acetate 4-Dimethylamino-benzo[a]phenazine- I11 -carboxylic acid 54 dimethylamino-ethyl)-amide 4-Methanesul fonylamino-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4 -Dimethylsulfamoyl-benzo[a]phenazine- I11 -carboxylic acid 57 dimethylamino-ethyl)-amide 4 -(Cyanomethyl-amino)-benzo[a]phenazine- I11 -carboxylic acid 59 (2-dimethylamino-ethyl)-amide 4, 1 O-Dimethoxy-benzo[a]phenazine- I11 -carboxylic acid dimethylamino-ethyl)-arnide 4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid 61 dimethylamino-propyl)-amide Benzo[a]phenazine-4,1 I1-dicarboxylic acid 4-amide 11 62 dimethylamine-ethyl)-amide]; triflouroacetic acid salt 4-Methoxy-benzo[a]phenazine- II-carboxylic acid dimethyl amino- 1,1-dimethyl-ethyl)-amide 4 -Methoxy-8-methyl-benzo[ajphenazine- I11 -carboxylic acid 67 dimethylamino-ethyl)-amide 4,1 O-Dihydroxy-benzo[a]phenazine- I11 -carboxylic acid 68 dimethylamino-ethyl)-amide_________ 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid 71 dimethylaminomethyl-propyl)-amide 4, 1 O-Dimethoxy-benzo[a]phenazine- I1I -carboxyl ic acid 72 dimethylamino- 1 -methyl-ethyl)-amide 9-Chloro-4-niethoxy-benzo[a]phenazine- I11 -carboxylic acid 73 dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid 74 -dirnethylaminomethyl-2-methyl-propyl)-amide 4-Methoxy-benzo[a]phenazine- II-carboxylic acid dimethylamino- I -hydroxym ethyl -ethyl) 4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid (1 76 -dimethyl.Iaminomethyl-2-phenyl-ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid 77 dinieth-ylamino- 1 -(S)-methyl-ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid 78 dimiethylamino- I -(R)-methyl-ethyl)-amide 4-N itro-benzo[a] phenazine-I 11-carboxylic acid 79 dimethylamino-1I -methyl-ethyl)-arnide 4-Nlethoxy-benzo[a]phenazine- I11 -carboxylic acid 81 dimethylamino- 1 -(S)-hydroxymethyl-ethyl)-amide 4-Methoxy- 1 -methylamino-benzo[a]phenazine-I 11-carboxylic 82 acid (2-diniethylamino-ethyl)-amide A598140spxc, 1 0-H ydroxy-4-methoxy-benzo[a]phenazine- I11 -carboxylic acid 83 (2-dimethylamino- 1 (R)-methyl-ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid 84 di methylaminomethyl-2-hydroxy-propyl)-amide ydroxy-4-methoxy-benzo[a]phenazine- I1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-piperidin- 86 I -yi-ethyl)-amide 4-Methoxy-benzo[a]phenazine- I11 -carboxylic acid [1I- 87 di methylamino- 1 -hyd rox yethyl)] -ethyl am ide 1 0-Amino-4-methoxy-benzo[a]phenazine- 11I -carboxylic acid 88 d imethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-morpholin- 89 4-yl-ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid (2-pyrrolidin- 1 -yi-ethyl)-amide__ 4-Methoxy-benzo[ajphenazine- 11 -carboxylic acid 91 hydrox y-ethyl)-amino] -ethyl)} -amide 4-Methoxy-benzo[a]phenazine- II-carboxylic acid 92 diethylamino-ethyl)-amide 4-Methoxy-9-methylsul fanyl-benzo[a]phenazine-I 11-carboxylic 93 -acid (-dimethylamino-ethyl)-amide 4,9-Dimiethoxy-benzo[a]phenazine- II-carboxylic acid 94 di methylami no-ethyl)-am ide 4,10 -Dimethoxy-benzo[a]phenazine- I1I -carboxylic acid dimethylamino- 1 (S)-hydroxymethyl-ethyl)-amide 4-Methoxy-benzo[a]phenazine- II-carboxylic acid 96 methylamino-ethyl)-amide I O-Hydroxy-4-methoxy-benzo[a]phenazine- 11I -carboxylic acid 97 (2-dimethylamino- I (S)-hydrox ymnethyl -ethyl)-am ide (R)-4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid( 1- 98 dimethylaminomethyl-2-methyl-propyl)-amide 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (1-methyl- 99 pyrrol idin-3 -(R)-yi)-ami de 4-Methoxy-benzo[a]phenazine- II-carboxylic acid 100 -dimethylamino-propyl)amide_________ Compounds of formula may be prepared by a process which comprises: treating an activated derivative of a compound of formula (11): 000000 0 0*00 0 *000 0 A 598 I N
R
R
3 R'
CO
2
H
R
2 wherein R' to R 7 are as defined above, with an amine of formula (III): Q, 8 9
H
2 N N(R
(II)
wherein Q, R 8 and R 9 are as defined above; or treating a compound of formula (IV):
R
N N f |(IV)
R
N R 7 3 R R' 0 10 wherein R' to R 7 and R" are as defined above, with a compound of formula (III) as defined above, either in an organic solvent or neat and at an elevated temperature; and if desired, converting one resulting benzo(a)phenazine-l 1-carboxamide derivative of formula into another such derivative, and/or converting a benzo[a]phenazine- 1carboxamide derivative of formula into a pharmaceutically acceptable salt thereof.
The optical purity of resulting compounds that have an optically active centre, for instance the benzo[a]phenazine-l 1-carboxamide derivatives of formula (Ia) and the salts thereof, may be determined by the addition of an NMR shift reagent such as 2,2,2-trifluoro- 1(9-anthryl) ethanol to NMR samples of the homochiral compounds.
The starting compounds of formula (II) and their esters (the compounds of formula are novel and thus constitute a further aspect of the present invention.
In step the carboxylic acid grouping in formula (II) may be activated as the corresponding acid chloride which may be obtained by treating the free carboxylic acid of A598140s 1 lcl formula (II) with thionyl chloride. Alternatively the carboxylic acid grouping can be activated by treatment with an appropriate amide-coupling reagent such as 1,1'carbonyldiimidazole.
The reaction between the activated derivative of the compound of formula (II) and the amine of formula (III) is typically conducted in an organic solvent. Suitable solvents include dimethylformamide and dichloromethane. The steps of activating the compound of formula (II) and treating the resulting activated derivative with the amine of formula (III) may take place without intermediate isolation of the activated derivative. In that case the process typically comprises combining the activating agent or coupling agent with the compound of formula (II) in an organic solvent and adding to the resulting reaction mixture the amine of formula (III).
A compound of formula (II) may be prepared by a process which comprises: treating a 1,2-naphthoquinone of formula 0O R4
V)
:O
R
2 4
R
H
2 N R
CO
2
H
or an ester or salt thereof, wherein R R and R 7 are as defined above for formula in an organic solvent, optionally in the presence of an acid. The solvent may be, for example, ethanol or acetic acid. By using 1 to 5 equivalents of mineral acid in the reaction mixture the regioselectivity of the reaction may be controlled. The use of about 2 equivalents or more of the acid, for instance from 1.5 to 5 equivalents, yields exclusively the desired regioisomer namely a benzo[a]phenazine- I1-carboxylic acid of formula The mineral acid is A59S140spCCI 11 preferably hydrochloric acid, more preferably concentrated hydrochloric acid. The salt of the benzoic acid of formula (VI) is typically the acetate salt.
The 1,2-naphthoquinone of formula may be prepared by treating the corresponding I-tetralone of formula (VII): 4
(VI)
R0 R3 R
R
2 wherein R' to R 4 are as defined above for formula with selenium dioxide in accordance with the procedure described in Tetrahedron Letters 1997, 4219-4220. The 1-tetralones of formula (VII) are known compounds or may be prepared from known compounds by published methods, for instance as described in the reference examples which follow, adapted where necessary using conventional laboratory techniques to achieve the desired definitions of R' to R 4 Published methods include those described in J. Med. Chem 1997, 40, 3014- 3024; J. Org. Chem. 1984 4226; JACS. 1994, 116 pp. 4852-4857 and J. Med. Chem. 1997 S p.1049.
15 The benzoic acids of formula (VI) are known compounds or may be prepared from known compounds using published methods, adapted where necessary using conventional laboratory techniques to achieve the desired definitions ofR 5 to R 7 Published methods include those described in J. Chem. Soc. Perkin Trans. I, 1984, p2019 and J. Med. Chem 1987, p.
84 3 20 A compound of formula (II) may also be prepared by a process which comprises: S treating a 2-halo-3-nitrobenzoic acid of formula (VIII): 0 2
N
OzN (VII) Hal
CO
2
H
A 59840spcca wherein Hal is Cl, Br, I or F, with a naphthylamine of formula (IX): R 4
(IX)
NH2
R
3
R
I
R
2 wherein R' to R 4 are as defined above for formula and submitting the resulting compound of formula 0 2
N
4
(X)
N
H
R 3 R'
C
0 2
H
R
2 wherein R1 to R are as defined above, to reductive cyclisation.
10 Step is typically conducted in an organic solvent. Suitable examples include butane-2,3-diol and ethylene glycol. Step is generally carried out by treatment of the compound of formula with NaBH 4 in sodium methoxide, sodium ethoxide or aqueous NaOH. The process is described in J. Med. Chem. 1987, 30, 843-851.
0. A compound of formula (IV) may be prepared by esterification of a corresponding 15 compound of formula (II) under standard reaction conditions, for instance by treatment of the free carboxylic acid compound of formula (II) with an alcohol of formula R"-OH wherein R' is as defined above.
Amines of formula (III) are known and commercially available compounds or may be produced from commercially available starting materials using conventional techniques, for instance as described in reference example 2 which follows.
A compound of formula may be converted into another compound of formula (I) by conventional methods. For instance, a compound of formula containing an esterified hydroxy group such as -OCOMe may be converted into a compound of formula (1) containing a free hydroxy group by hydrolysis, for instance alkaline hydrolysis. A compound of formula containing a free hydroxy group may be converted into a compound A5QJ140spocc 13 of formula containing an esterified hydroxy group by esterification, for instance by reaction with a suitable carboxylic acid, acid halide or acid anhydride. A compound containing a free hydroxy group may also be converted to a compound containing a carbamic acid ester grouping, for instance by treatment with triethylamine and ethyl isocyanate in an aprotic polar solvent, for instance dimethylformamide.
A compound of formula containing a nitro group may be converted into a compound of formula containing an amino group by reduction, for instance by treatment with indium and a saturated NH 4 C solution in an organic solvent.
A compound containing a Ci-C 6 alkoxy group may be converted into a compound containing a hydroxy group, for instance by treatment with boron tribromide in a halogenated hydrocarbon solvent, for instance dichloromethane, or with sodium thioethoxide in dimethyl formamide. A compound containing a hydroxy group may be converted into a compound containing an optionally substituted Ci-C 6 alkoxy group, for instance by treatment with an appropriate alkylating agent in the presence of a base. A compound containing a carboxy group may be converted to a compound containing a hydroxymethyl group by reduction, for instance by treatment with LiAIH 4 in tetrahydrofuran.
A compound containing a halogen may be converted into a compound containing an alkylsulfanyl or alkoxy group, for instance by treatment with a thioalkoxide or alkoxide salt, respectively, in an organic solvent. A compound containing a nitrile group may be converted into a compound containing an N-hydroxycarbamimidoyl group, for instance by treatment with hydroxylamine (optionally in the form of a salt) in the presence of a base such as potassium carbonate.
A compound substituted by alkylaminomethyl at a benzene ring position may be prepared under Mannich reaction conditions by treating a compound that is substituted by 25 hydroxy ortho to the (unsubstituted) ring position in question with acetic acid followed by treatment with an alkylamine and a solution of formaldehyde in water. A compound of formula may be acetylated, for instance on an amine group to form an acetylamino substituent, by treatment with acetyl chloride under suitable conditions.
Benzo[a]phenazine-l 1-carboxamide derivatives may be converted into pharmaceutically acceptable salts, and salts may be converted into the free compound, by conventional methods. Pharmaceutically acceptable salts of the benzo[a]phenzine-l 1carboxamide derivatives of formula include salts of inorganic acids such as hydrochloric acid, hydrobromic acid and sulfuric acid, and salts of organic acids such as acetic acid, oxalic acid, malic acid, methanesulfonic acid, trifluoroacetic acid, benzoic acid, citric acid and A598140spc 14 tartaric acid. In the case of compounds of formula 1 wherein any one of R'-R 4 and R' 1 is COOH, the salts include both the above-mentioned salts and the salts of sodium, potassium, calcium and ammonium, which are prepared by treating the compound of formula 1 with or the acid salts with the corresponding metal base or ammonia.
Multi-drug resistance (MDR) is a phenomenon whereby cells which are typically sensitive to chemotherapeutic agents develop resistance to those agents and to a wide range of unrelated drugs. MDR represents a major obstacle in the successful clinical therapy of cancer. Cancer cells which exhibit MDR can display a number of diverse cellular alterations including overexpression of P-glycoprotein overexpression of multidrug resistance associated protein (MRP), reduction in levels of topoisomerase II (termed atypical drug resistance) and qualitative changes in expression of topoisomerase I. MDR is a very important clinical problem with many tumors developing resistance to many chemotherapeutic agents including those that specifically target topoisomerase I and/or topoisomerase II.
By simultaneously inhibiting topoisomerase I and II, compounds such as DACA (Finlay et al, Eur. J. Cancer 32A, 708-714, 1996) have shown no loss of activity when S resistance develops to camptothecin or amsacrine due to alteration of either topoisomerase I or II respectively. Qualitatively different cell cycle events have been obtained with inhibitors of topoisomerase I or II. (Kaufman, Biochim. Biophys. Acta 1400, 195-212, 1998).
20 Joint inhibitors of topoisomerases I and II appear to combine the properties of the individual specific inhibitors and act across the cell cycle (Haldane et al, Cancer Chemother.
Pharmacol. 32: 463-470, 1993), resulting in a greater antitumour activity (Riou et al, Cancer Res. 53, 5987-5993, 1993).
MDR due to the overexpression of membrane transporters such as P-glycoprotein (Gottesman et al, Annu. Rev. Biochem. 62, 385-427, 1993) and MRP (Loe et al, Eur. J.
Cancer 32A, 945-957, 1996) is known to reduce the clinical efficacy of chemotherapeutic S agents such as paclitaxel, etoposide and doxorubicin. Agents that avoid such MDR mechanisms are predicted to show therapeutic benefit in the treatment of cancer.
Benzo[a]phenazine-l 1-carboxamide derivatives of formula I, their pharmaceutically acceptable salts and hydrates and solvates thereof (hereinafter referred to as "the present compounds") have been found in biological tests to have activity as inhibitors of topoisomerase I and II. In one aspect of the invention the present compounds are joint inhibitors of topoisomerase I and topoisomerase II.
A 5Q81 4spec The present compounds may therefore be used as inhibitors of topoisomerase I.
Alternatively the present compounds may be used as inhibitors oftopoisomerase II. In a further embodiment they may be used as joint inhibitors of topoisomerase I and topoisomerase II. They have been shown to kill human tumour cells and avoid MDR mechanisms. They therefore have potential in the treatment of cancer. Examples of types of cancer that the present compounds can be used to treat include leukaemias, lymphomas, sarcomas, carcinomas and adenocarcinomas. Specific examples include breast, colon, brain, lung, ovary, pancreatic, stomach and skin cancer.
A human or animal patient harbouring a tumour may be treated by a method comprising the administration thereto of one of the present compounds. In particular, a method of treating human tumours, including those which express MDR, for instance the types of MDR referred to above, comprises administering a therapeutically effective amount of one of the present compounds to a patient harbouring a tumour. All types of tumour may thus be treated, both those which express MDR and those which do not. The present compound is administered in an amount effective to reduce or eliminate the tumour. In one aspect of the invention the present compound is administered orally. In another aspect the present compound is administered by a parenteral route, for instance intravenously.
p reeOwing to their activity as inhibitors of topoisomerase I and topoisomerase II the present compounds may also be used as antiviral, antibacterial or antifungal agents.
The present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously. The present compounds may therefore be given by injection or infusion.
The dosage depends on a variety of factors including the age, weight and condition of :25 the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 500 mg/kg, most commonly in the range of 0.01 to 100 mg/kg body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration.
A benzo[a]phenazine- I1-carboxamide derivative of formula or a pharmaceutically acceptable salt thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent. The compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form. An agent for use in the treatment of A59S I tumours, including those which express MDR, comprising one of the present compounds is therefore provided.
The present compounds may be administered in any conventional form, for instance as follows: A) Orally, for example, as tablets, coated tablets, dragees, troches, lozenges, aqueous or oily suspensions, liquid solutions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, dextrose, saccharose, cellulose, corn starch, potato starch, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, maize starch, alginic acid, alginates or sodium starch glycolate; binding agents, for example starch, gelatin or acacia; lubricating agents, for example silica, magnesium or calcium stearate, stearic acid or talc; effervescing mixtures; dyestuffs, sweeteners, wetting agents such as lecithin, polysorbates or 20 lauryl sulphate. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. Such preparations may be manufactured in a known manner, for example by means of mixing, granulating, tableting, sugar coating or film coating processes.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is present as such, or mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone gum tragacanth and A5981d40spcC 17 gum acacia; dispersing or wetting agents may be naturally-occurring phosphatides, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides for example polyoxyethylene sorbitan monooleate.
The said aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate, one or more colouring agents, such as sucrose or saccharin.
Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by this addition of an antioxidant such as ascorbic acid. Dispersible powders and granules suitable S. for preparation of an aqueous suspension by the addition of water provide the active 20 ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-inwater emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oils, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally occuring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, sorbitol or sucrose.
In particular a syrup for diabetic patients can contain as carriers only products, for example A598140spcci 18 sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose.
Such formulations may also contain a demulcent, a preservative and flavouring and coloring agents; B) Parenterally, either subcutaneously, or intravenously, or intramuscularly, or intrasternally, or by infusion techniques, in the form of sterile injectable aqueous or oleaginous suspensions. This suspension may be formulated according to the known art using those suitable dispersing of wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic paternally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition fatty acids such as oleic acid find use in the preparation ofinjectables; C) By inhalation, in the form of aerosols or solutions for nebulizers; D) Rectally, in the form of suppositories prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols; Topically, in the form of creams, ointments, jellies, collyriums, solutions or suspensions.
Daily dosages can vary within wide limits and will be adjusted to the individual requirements in each particular case. In general, for administration to adults, an appropriate daily dosage is in the range of about 5 mg to about 500 mg, although the upper limit may be exceeded if expedient. The daily dosage can be administered as a single dosage or in divided dosages.
The invention will be further illustrated in the Examples which follow.
A 5S8140spci Reference Example 1: Preparation of Compounds of General Formula UDI Reference Example IA. 4-Methoxy-benzofalphenazine-I 1-carboxylic acid (11.1) A mixture of 5-methoxy-[l, 2] naphthoqu inone (prepared by treatment of methoxytetralone with selenium dioxide, A. Bekaert et al Tetrahedron Letters 38,24, 42 19- 4220, 1997)(1.98g) 2,3-diamino-benzoic acid, diacetate salt Chem. Soc. Perkin. Trans 1, 1984,p20l9) (4.03g) and conc. hydrochloric acid(2.2mL) was heated to reflux in ethanol(2OmL) for 4 hours. The reaction mixture was cooled and the precipitate collected by filtration, and washed with ethanol and ether to yield the title compound as a beige solid (2.74g).
NMR: (DMSO) 4.05 7.50(1 7.84-7.87(lH,m), 7.99(1 8.08-8.10(1 H,m), 8.41 -8.49(3H,m), 8.63(1 H,d).
Reference Example lB3. 4-Methyl-benzoralphenazine-I 11-carboxylic acid (11.2) 5-Methyl- I-tetralone was prepared from o-tolualdehyde according to the literature (J .Mcd Chem 1997,40,3014-3024). Treatment of 5-methyl-i -tetralone with selenium dioxide as described in Reference Example IA yielded 5-methyl-[1,2]naphthoquinone. This was reacted with 2,3-diamino-benzoic acid, diacetate salt, as described in Reference Example I A to yield the title compound.
20 NMR. d6-DMSO 9.02(l 8.5 1(1IH,dd), 8.47-8.44(2H,m), 8.1 l-8.05(2H,m), 7.85- 7.78(2H,m), 2.79(3H,s).
Commencing with the appropriately substituted aldehydes, the following compounds of Formula (11) were prepared in an analogous manner: 4-Fluoro-benzo[a]phenazine- II-carboxylic acid (11.3) was prepared from 2fluorobenzaldehyde NMR, d6-DMSO, 8.97(lIH,d), 8.5 1(1 H,dd), 8.43(l H,dd), 8.38(l H,d), 8.1I 1-8.06(2H,m), 7.95(I 7.80(l H,m); 3 ,4-Dimethoxy-benzo[a]phenazine-I 11-carboxyl ic acid (11.4) was prepared from 2,3di1methoxybenzaldehyde; NMR, CDC13, 8.79(1 8.48(2H,d),8.37(1 8.05(l 7.95(1 H,d),7.76( I H,d), 4.04(3H,s), 3.98(3H,s).
Reference Example IC. 4-Bromo-benzoralphenazine- 11 -carboxylic acid (11.5) 2-Bromobenzyl bromide was converted into 5-bromotetralone according to the literature Org. Chem. 1984, p4226). Treatment of 5-bromotetralone w"ith selenium dioxide A5')8140q 1 ,c, as described in Referene Example 1A yielded 5-bromo-[1,2]naphthoquinone, which was coupled with 2,3-diamino-benzoic acid, diacetate salt, as described in Reference Example 1A to yield the title compound.
NMR d6-DMSO, 9.24(lH,d), 8.48(2H,m), 8.33(1H,m), 8.26(1H,m), 8.20(1H,d), 8.08(lH,t), 7.87(IH,t) Reference Example 1D. 4-Cyano-benzo[a]phenazine- l -carboxylic acid (11.6) To a solution of 5-bromotetralone (see Reference Example C)(1 5.0g) in N,Ndimethylformamide (20mL) was added copper cyanide(6.39g) and the reaction mixture heated to reflux for 20 hours. The reaction mixture was then cooled to 80°C and a solution of FeC1 3 .6H 2 0 (24g) in water (38mL) was added. After stirring for a further 45 minutes the reaction mixture was cooled, diluted with water, extracted into toluene, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield 5-cyano-1-tetralone as a yellow solid.
Treatment of 5-cyano-1-tetralone with selenium dioxide as described in Reference Example 1A yielded the corresponding 5-cyano-[1,2]naphthoquinone, which was coupled with 2,3-diamino-benzoic acid, diacetate salt as described to yield the title compound.
NMR (d6-DMSO), 8.10-8.18(2H,m), 8.33(1H,d), 8.43(2H,m), 8.48-8.54(2H,m), 9.48(1H,d).
S MS DCI/NH3 m/z 300 (MH+) Reference Example lE. 4-Chloro-benzo[alphenazine-11-carboxylic acid (II.7) was prepared from a-tetralone according to the literature Am.
Chem. Soc. 1994, p4852). A mixture of 5-amino-l-tetralone (80mg) and concentrated hydrochloric acid (lmL) was cooled to 0OC. A solution of sodium nitrite (35mg) in water :25 (0.5mL) was added dropwise to the stirring solution. The cold diazonium solution was then poured rapidly onto a stirring solution of copper chloride (62mg) in concentrated hydrochloric acid (lmL). The reaction mixture was allowed to warm to ambient temperature and then stirred for 1.5 hours. The mixture was then extracted with ethyl acetate, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield 5-chloro-l-tetralone as a brown solid (87mg).
Treatment of 5-chloro-tetralone with selenium dioxide as described in Reference Example IA yielded 5-chloro-[ 1,2]naphthoquinone which was coupled with 2,3-diaminobenzoic acid, diacetate salt, as described in Reference Example 1A to yield the title compound.
A598140Spccl 21 Reference Example IF. 4-Methanesulphonyl-benzo[a]phenazine- 11-carboxylic acid (11.8) was prepared from 5-hydroxy-l-tetralone according to the literature Med. Chem. 1997, p1049). A mixture of (221mg) and 3-chloroperbenzoic acid (595mg) was stirred at room temperature for 2 hours.
The reaction mixture was then extracted with dichloromethane, washed with water, dried (Na 2
SO
4 and the solvent removed in vacuo to yield 5-methanesulphonyl-l-tetralone as an off-white solid (210mg) Treatment of 5- methanesulphonyl-1-tetralone with selenium dioxide as described in Reference Example 1A yielded 5-methanesulfonyl-[1,2]naphthoquinone which was coupled with 2,3-diamino-benzoic acid, diacetate salt, as described in Reference Example 1A to yield the title compound.
NMR, d6-DMSO, 9.61(1H,d), 9.03(1H,d), 8.56(2H,m), 8.43(1H,d), 8.32(lH,m), 8.16(2H,m), 3.51(3H,s). MS, DCI/NH3 m/z 353 Reference Example 1G. 4-Azido-benzoralphenazine-l 1-carboxylic acid (11.9) was prepared from oe-tetralone according to the literature Am.
Chem. Soc. 1994, p4852). To a cold solution of 5-amino-l-tetralone (415mg) in water (2mL) S and concentrated hydrochloric acid (5mL) was added a solution of sodium nitrite (186mg) in water (1.2mL), maintaining low temperature. After 40 minutes a solution of sodium azide 20 (184mg) in water (1.2mL) was added dropwise. The reaction mixture was allowed to warm to S room temperature. After one further hour the reaction was quenched with water, extracted into ether, washed with sodium bicarbonate solution, dried (MgSO 4 and the solvent removed in vacuo to yield crude material which was purified using flash chromatography to yield azido-l-tetralone (77mg).
25 Treatment of 5-azido-l-tetralone with selenium dioxide as described in Reference Example 1A yielded 5-azido-[ 1,2]naphthoquinone which was coupled with 2,3-diamino-benzoic acid, diacetate salt as described in Reference Example 1A to yield the title compound.
Reference Example 1H. Benzo[a]phenazine-4,11-dicarboxylic acid 4-methyl ester (II. Methyl 5-oxo-5,6,7,8-tetrahydro-1-naphthoate was prepared according to the literature Org. Chem. 1976, p2918) from 2-methyl-2,6,7,8-tetrahydro-chromen-5-one (Tetrahedron Letters, 1975, p3407). Treatment of methyl 5-oxo-5,6,7,8-tetrahydro-1-naphthoate with selenium dioxide as described in Reference Example IA yielded the corresponding 1,2naphthoquinone, 5,6-dioxo-5,6-dihydro-naphthalene-1-carboxylic acid methyl ester, which A5S8140specC was coupled with 2,3-diamino-benzoic acid, diacetate salt, as described in Reference Example I A to yield the title compound.
NMR, d6-DMSO, 9.47(1H,d), 9.02(1H,d), 8.53(1H,d), 8.44(2H,m), 8.20(1lH,d), 8.10(2H,m), 4.03(3H,s).
Reference Example Ii. 4-Ethoxy-benzoralphenazine- 11 -carboxylic acid (II.11) A mixture of 5-hydroxy-1-tetralone (2.00g) and sodium hydroxide (493mg) was warmed in ethanol (40mL) to 50"C. Ethyl iodide (3.94mL) was then added and the reaction mixture was heated at reflux for 16 hours. The reaction mixture was diluted with 2N hydrochloric acid, extracted into ethyl acetate, dried and the solvent removed in vacuo to yield 5-ethoxy-l-tetralone as a white solid (2.06g) Treatment of 5-ethoxy-1-tetralone with selenium dioxide as described in Reference Example IA yielded 5-ethoxy-[1,2]naphthoquinone which was coupled with 2,3-diaminobenzoic acid, diacetate salt as described to yield the title compound.
NMR: d6-DMSO. 1.52(3H,q), 4.33(2H,t), 7.50(1H,d), 7.85-7.90(1H,m), 8.00(1H,d), 8.08- 8.11(1H,m), 8.45-8.55(3H,m), 8.68(1H,d).
Reference Example 1J. 4-Methylsulfanvl-benzora]phenazine- 11-carboxylic acid (11.12) To a stirred solution of 4-fluoro-benzo[a]phenazine-l 1-carboxylic acid (II.3,see o Reference Example 1B)( 58mg) in dry DMSO(3mL) was added sodium S thiomethoxide(55mg) and the reaction mixture heated at 100C for 1.5 hours and 130*C for I hour.The reaction mixture was then cooled to room temperature, quenched with acetic acid, extracted with ethyl acetate, washed with water, dried and the solvent removed in vacuo to yield the title compound as a red solid(37mg).
25 NTMR, d6-DMSO, 9.00(1H,d), 8.52(2H,m), 8.45(IH,d), 8.11(2H,m), 7.91(2H,m), 2.70(3H,s).
MS, DCI/NH3, m/z=321(MH+, 100%) Reference Example 1K. 4-Benzvloxy-benzora]phenazine-l l-carboxylic acid (II.13) To a solution of 4-methoxy-benzo[a]phenazine- 1-carboxylic acid (11.1, see Reference Example IA)(441mg) in dichloromethane(30mL) cooled to OC was added a 1.OM solution of boron tribromide in dichloromethane(7.25mL). The reaction mixture was allowed to warm to room temperature and then stirred for 16 hours. The mixture was then poured onto ice/water yielding 4-hydroxy-benzo[a]phenazine- 11 -carboxylic acid as a red/brown solid which was collected by filtration and air dried (230mg).
AS9814OspcI 23 NMR: d6-DMSO. 7.35(lH,d), 7.75(H,m), 7.92(lH,d), 8.08(lH,m), 8.47-8.55(4H,m), 10.72(1H,broad).
A mixture of 4-hydroxy-benzo[a]phenazine- 1l-carboxylic acid (80mg), sodium hydroxide(34mg) and benzyl bromide(100p L) in ethanol(2mL) was heated to reflux for 4 hours. The reaction mixture was then cooled, diluted with ethyl acetate, washed with dilute acid, dried(MgSO 4 and the solvent removed in vacuo to yield the crude title compound as a brown NMR: d6-DMSO. Includes 5.35(2H,s) The following compounds were prepared in an analogous manner from 4-hydroxybenzo[a]phenazine-l l-carboxylic acid using the appropriate alkylating reagent; 4-Prop-2-ynyloxy-benzo[a]phenazine-1 1-carboxylic acid (II.14) was prepared using propargyl bromide; 4-Isobutoxy-benzo[a]phenazine- I1-carboxylic acid (II.15) was prepared using isobutyl bromide; 4-(4-Chloro-benzyloxy)-benzo[a]phenazine- Il -carboxylic acid (II.16) was prepared using pchlorobenzyl bromide; 4-(2-Methoxy-ethoxy)-benzo[a]phenazine-l l-carboxylic acid (II.17) was prepared using 2bromoethyl methyl ether; 4-Ethoxycarbonylmethoxy-benzo[a]phenazine- I1-carboxylic acid (II.18) was prepared using ethyl bromoacetate. Sodium ethoxide in dry ethanol was used for this reaction; 4-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-benzo[a]phenazine- 11 -carboxylic acid (II.19) was prepared using tert-butyl-(2-iodo-ethoxy)-dimethyl-silane. The tert-Butyl-(2-iodo- S ethoxy)-dimethyl-silane was prepared using standard procedures from 2-iodo-ethanol.
:25 Reference Example 1 L. Benzo[alphenazine- Il -carboxvlic acid (11.20) .A mixture of 1,2-naphthoquinone(commercially available, 2.0g) and 2,3-diaminobenzoic acid, diacetate salt (3.79g) was heated to reflux in acetic acid(30mL) for 2 hours.
The reaction mixture was cooled and the solvent removed in vacuo to yield a gum. This was purified using flash chromatography to yield a 2:1 mixture of the desired title compound to the undesired benzo[a]phenazine-8-carboxylic acid (840mg). The two isomers were separated after further modification (see Reference Example 3B below) NMR d6-DMSO,includes 9.07-9.09(lH,m), 9.21-9.22(1lH,m). 2:1 ratio A598140spec Reference Example 1M. 4-Methylsulfamoyl-benzo[ralphenazine- 11 -carboxylic acid (11.21)and 3-methylsulfamoyl-benzora]phenazine- 11 -carboxylic acid (11.22) Benzo[a]phenazine-1 1-carboxylic acid methyl ester (IV.20, see Reference Example 3B, 220mg) was heated under nitrogen to 180C in chlorosulphonic acid(2mL) for 6 hours.
The reaction was then cooled, poured onto ice/water and the pale yellow solid collected by filtration to give approximately a 1:1 mixture of 4-chlorosulfonyl-benzo[a]phenazine-1 1carboxylic acid and 3-chlorosulfonyl-benzo[a]phenazine- 11l-carboxylic acid (182mg). NMR d6-DMSO, includes 9.41 9.30(IH,d).
The mixture of 4-chlorosulfonyl-benzo[a]phenazine- 11-carboxylic acid and 3chlorosulfonyl-benzo[a]phenazine- I1-carboxylic acid (182mg) was dissolved in To this was added a 40% solution of methylamine in water and the reaction mixture was stirred vigorously for 4 hours. The reaction mixture was then poured onto dichloromethane, acidified (2N HCI), extracted into dichloromethane, dried (MgSO 4 and the solvent removed in vacuo to give a -1:1 mixture of the title compounds (160mg). The two isomers were separated after further chemical modification.
NMR (CDCI3 +d4MeOH) includes 9.38(1H,s), 9.22(lH,d), 2.61(3H,s), 2.55(3H,s).
4-Dimethylsul famoyl-benzo[a]phenazine- 11 -carboxylic acid (11.23)and 3dimethylsulfamoyl-benzo[a]phenazine-1 I1-carboxylic acid (11.24) were prepared in an analogous manner by reaction of dimethylamine with the mixture of 4-chlorosulfonyl- S 20 benzo[a]phenazine- 11-carboxylic acid and 3-chlorosulfonyl-benzo[a]phenazine-l 1carboxylic acid. The two isomers were separated after further chemical modification. NMR (d6-DMSO) of mixture includes 9.06(1H,d), 9.42(lH,s), 2.93(6H,s) S* 4-Sulfamoyl-benzo[a]phenazine- I1-carboxylic acid (11.25) and 3-sulfamoylbenzo[a]phenazine- I1-carboxylic acid (11.26) were prepared in an analogous manner by 25 reaction of ammonium hydroxide with the mixture of 4-chlorosulfonyl-benzo[a]phenazine- I-carboxylic acid and 3-chlorosulfonyl-benzo[a]phenazine- I1-carboxylic acid. The two isomers were separated after further chemical modification. NMR (d6-DMSO) of mixture includes, 9.39(1H,d), and 9.60(1H,s) Reference Example IN. 4-Nitro-benzoralphenazine-11-carboxlic acid (11.27) and 3-nitrobenzoralphenazine- 11-carboxvlic acid (11.28) Concentrated sulphuric acid (5mL) and concentrated nitric acid (5mL) were mixed together at OoC. To this mixture was added benzo[a]phenazine-l 1-carboxylic acid (11.20) (100mg) and the reaction mixture allowed to warm slowly to room temperature. After 24 A59QS140spec hours the reaction mixture was poured onto water yielding a yellow precipitate. This was collected by filtration to yield a 4:1 mixture of4-nitro-benzo[a]phenazine- 11-carboxylic acid (11.27) and 3-nitro-benzo[a]phenazine-l 1-carboxylic acid (11.28). The two isomers were separated after further chemical modification.
NMR, d6-DMSO, includes 9.82(1H,d), 9.46(1H,d), 1:4 ratio MS MH@320 Reference Example 10. 4-Amino-benzo[a]phenazine- 1-carboxylic acid (11.29) and 3amino-benzora]phenazine- 11-carboxylic acid To the 4:1 mixture of 4-nitro-benzo[a]phenazine- 11-carboxylic acid (11.27) and 3nitro-benzo[a]phenazine- 11-carboxylic acid (II.28)(52mg) in ethanol (5mL) from Reference Example IN was added ammonium chloride solution (3mL) and indium (cat.) The reaction mixture was heated to reflux, then cooled and filtered through a bed of celite. The filtrate was diluted with water, extracted into dichloromethane, dried (MgSO 4 and the solvent removed in vacuo to yield the title compounds as a mixture (48mg). Separated after further modification.
NMR, d6-DMSO, 6.95(1H,d), 7.55(1H,t), 7.75(2H,m), 8.05(2H,m), 8.20(1H,d), 8.65(1H,d) Reference Example 1P. 3-Bromo-4-hydroxv-benzo[a]phenazine- 11-carboxylic acid (11.31) go*.: A mixture of 4-hydroxy-benzo[a]phenazine-l 1-carboxylic acid (see Reference Example 1K, 102mg) and bromine(0.04mL) was stirred in chloroform (3mL) at room temperature for 20 hours. The solvent was removed in vacuo and the residue was purified using flash chromatography (10% methanol in dichloromethane) to yield the title compound (24mg) as a yellow-brown solid.
:25 MS DCI/NH3,MH+ 369/371(1:1) NMR (CDC13), 7.94(lH,d), 8.1-8.2(2H,m), 8.52-8.62(2H,m), 9.1(lH,d).
Reference Example 10. 2-Nitro-benzo[a]phenazine- 11-carboxylic acid (11.32) 7-Nitro-l-tetralone was prepared according to the literature Am. Chem. Soc, 1994, 116, pp4852-4857). Treatment of 7-nitro-l-tetralone with selenium dioxide as described in Reference Example 1A yielded the corresponding 7-nitro-[l,2]naphthoquinone, which was coupled with 2,3-diamino-benzoic acid, diacetate salt, as described in Reference Example 1A to yield the title compound.
A59S140speci Reference Example 1IR. 2-Methoxv-benzora]phenazine- 11-carboxvlic acid (11.33) 8-Amino-naphthalen-2-ol was prepared from 8-amino-2-naphthalenesulphonic acid (commercially available) according to the literature Org. Chem. 1949, p351). To a solution of 8-amino-naphthalen-2-ol (8.00g) in dry N,N-dimethylformamide (80mL) was added sodium hydride (60% dispersion in mineral oil, 3.2g) carefully. After stirring for 4 hours the reaction mixture was cooled in an ice bath and methyl iodide (3.13mL) was added dropwise. The reaction mixture was then stirred at room temperature for 3 days. Water was then added and the volatiles were removed in vacuo. The residue was dissolved in chloroform, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield a dark oil. This was purified using flash chromatography (chloroform) to yield 7-methoxynaphthalen-1-ylamine as a dark brown liquid (2.92g).
7-Methoxy-naphthalen-l-ylamine was treated with 2-bromo-3-nitro-benzoic acid according to the analogous procedure described by G.W.Rewcastle et al Med. Chem.
1987, p843) to yield 2-(7-methoxy-naphthalen-1-ylamino)-3-nitro-benzoic acid. Reductive cyclisation using sodium borohydride Med Chem. 1987, p843) yielded the desired title compound.
NMR, d6-DMSO, 14.44(1H,broad,s), 8.55(1H,d), 8.48(1H,dd), 8.42(1 H,dd), 8.23(1 H,d), 8.10-8.04(2H,m), 7.86(1H,d), 7.56(1 H,dd), 4.02(3H,s).
MH+ @305 3-Methoxy-benzo[a]phenazine- 11-carboxylic acid (11.34) was prepared in analogous S manner starting with 5-amino-naphthalene-2-sulfonic acid (commercially available).
NMR, d6-DMSO, 14.60(1lH,broad,s), 8.94(1 8.51(2H,d), 8.23(1 8.10-7.96(2H,m), S 7.67(1H,d), 7.55(1H,dd), 3.99(3H,s).
MH+ @305 Reference Example 1S. 9-Bromo-4-methoxy-benzora]phenazine- I1-carboxylic acid (11.35) A mixture of 4-methoxy-benzo[a]phenazine- 11 -carboxylic acid (II.1)(100mg) and drops) in chloroform(7mL) was stirred at room temperature for 3 days. The reaction mixture was reduced in vacuo and the desired product was isolated using flash chromatography MS MH+ @383/385 (1:1) NMR ,CDCI3, 14.47(1H,br,s), 8.86(1H,d), 8.33(1H,d), 7.95(1H,t), 7.78(1H,d), 6.97(1H,d), 6.12(1H,d), 5.75(1H,d), 3.94(3H,s) AS9 8140,1cr Reference Example IT. 4,10-Dimethoxy-benzora]phenazine-11-carboxylic acid (11.36) 2-Amino-6-methoxy-3-nitro-benzoic acid methyl ester was prepared using a procedure analogous to that described in the literature (Kim et al, J.Med. Chem. 1993, p2335). Hydrolysis of the methyl ester was achieved using potassium hydroxide in refluxing ethanol for 2 hours to yield 2-amino-6-methoxy-3-nitro-benzoic acid. Hydrogenation of the nitro group was performed in acetic acid/water over palladium on carbon catalyst on the Parr apparatus at 50psi H 2 to yield 2,3-diamino-6-methoxy-benzoic acid. This was reacted with methoxy-[1,2]naphthoquinone as described in Reference Example IA to yield the desired title compound.
NMR, d6-DMSO, 4.05(3H,s), 4.10(3H,s), 7.45(H,d), 7.78-7.82(H,m), 7.92(1H,d), 8.03(1 H,d),8.36-8.40(2H,m), 8.78(1H,d) Reference Example I U. 4-Methoxy-8-methyl-benzoralphenazine- 11 -carboxylic acid (11.37) 2,3-Diamino-4-methylbenzoic acid was prepared from 4-methyl anthranilic acid according to the method described by Rewcastle et al (J.Med Chem. 1987, p843). This was reacted with 5-methoxy-[l1,2]naphthoquinone as described in Reference Example IA to yield the desired title compound.
20 NMR, d6-DMSO, 2.97(3H,s), 4.06(3H,s), 7.50(lH,d), 7.85-7.90(lH,m), 7.97(1H,d),8.02( 8.45-8.50(2H,m), 8.57(1H,d).
Reference Example IV. 9-Chloro-4-methoxy-benzoralphenazine-11-carboxylic acid (11.38) 5-Chloro-3-nitroanthranilic acid was prepared according to the procedure described by Flippin et al (Biorg. Med. Chem. Letts 1996, p477). Hydrogenation of this material in ethyl acetate using palladium on carbon at 50psi H 2 for 2 hours yielded 2,3-diamino-5-chlorobenzoic acid. This was reacted with 5-methoxy-[1 ,2]naphthoquinone as described in Reference Example IA to yield the desired title compound.
NMR, d6-DMSO, 4.05(3H,s), 7.48(1H,d), 7.82-7.86(H,m), 7.92(1H,d), 8.30(1H,d), 8.48(1H,d), 8.54(1 8.68(1H,d), 14.1(1H,broad).
A59SIO40spcci Reference Example 2 Preparation of Compounds of General Formula (III) Reference Example 2A. 4-Aza-DL-leucine methyl ester. hydrochloride (III.1) Methanol (150mL) was saturated with anhydrous hydrogen chloride gas. To this was added 4-aza-DL-leucine (4.86g)(commercially available) and the reaction mixture was stirred overnight at room temperature. The solvent was removed in vacuo to yield the title compound (quantitative yield) Reference Example 2B. N',N -Dimethyl-butane-1,2-diamine (111.2) Methyl N-(tert-butoxycarbonyl)-2-aminobutyrate was prepared as described in the literature( J.Med. Chem. 1989,p1886). Treatment of this compound with diisobutyl aluminium hydride in toluene at -780 C for 1.5 hours yielded the corresponding aldehyde (prep see H.W. Scheeren et al, J. Org. Chem. 1990, p3998).
A mixture of the aldehyde (1.85g), dimethylamine hydrochloride (1.61g), sodium acetate (1.21g) and sodium cyanoborohydride (0.83g) in methanol was stirred at room temperature for 24 hours. The pH was adjusted to 6-7 using acetic acid and monitored during the reaction. The reaction mixture was then concentrated in vacuo, and the residue dissolved in ethyl acetate and washed with water. The organic layer was dried (MgSO4) and the solvent removed in vacuo to yield a colourless oil, which was purified using flash chromatography to o yield the desired dimethylamine derivative as a pale oil (0.56g). To this compound (260mg) 20 was added a 4.0M solution of HCI in dioxane(2mL) carefully and the reaction mixture stirred or 90 minutes. The reaction mixture was then concentrated in vacuo to yield the desired title compound as an off-white solid (quantitative yield).
Reference Example 2C. 3N',N'-Trimethyl-butane-1, 2-diamine. Hydrochloride salt (111.3) N-(tert-butoxycarbonyl)-DL-valine methyl ester was prepared from DL-valine using standard preparative techniques. This was converted into the desired title compound using an analogous procedure to that described in Reference Example 2B.
Enantiomerically pure (R)-3N',N'-Trimethyl-butane-1, 2-diamine. Hydrochloride salt (lII.3.a) was prepared by using D-valine as the starting material.
Reference Example 2D. N',N'-Dimethyl-3-phenyl-propane-l,2-diamine. Hydrochloride salt (111.4) N-(tert-butoxycarbonyl)-DL-phenylalanine methyl ester was prepared from DLphenylalanine using standard preparative techniques. This was converted into the desired title A 58140speci compound using an analogous procedure to that described in Reference Example 2B.
Reference Example 2E. (S)-N
N
-Dimethyl-propane-1,2-diamine. Hydrochloride salt (111.5) 2-(S)-[N-(tert-Butoxycarbonyl)amino]propanal was prepared from L-alanine according to the procedure described in the literature(Chakravarty et al, J. Med. Chem 1989, p1886). A mixture of the aldehyde(2.62g), dimethylamine hydrochloride(2.47g), sodium acetate(1.99g) and sodium cyanoborohydride(1.43g) in methanol (45mL) was stirred at room temperature for 18 hours. The reaction mixture was dissolved in ethyl acetate, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield a viscous oil. This was dissolved in dichloromethane, extracted with citric acid, basified with sodium hydroxide, and re-extracted with ethyl acetate. The organic layer was reduced in vacuo to yield the dimethylamino derivative as a white solid (586mg).
To this compound (366mg) was added a 4.0M solution of hydrochloric acid in dioxane (5.5mL) at room temperature. After stirring for 30mins the volatiles were removed in vacuo to yield the desired title compound as a viscous oil (313mg) Reference Example 2F. (R)-N',N'-Dimethyl-propane-1,2-diamine. Hydrochloride salt (II.6) 20 2-(R)-[N-(tert-Butoxycarbonyl)amino]propanal was prepared from D-alanine Meester hydrochloride according to the procedure described in the literature(Chakravarty et al, J.
Med. Chem 1989, p1886).
A mixture of the aldehyde(16.21g), dimethylamine hydrochloride(15.28g), sodium acetate( 1.53g) and sodium cyanoborohydride(8.24g) in methanol (250mL) was stirred at 25 room temperature for 18 hours maintaining pH at 6-7 with AcOH. The reaction mixture was dissolved in ethyl acetate, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield a viscous oil which was purified using flash chromatography to yield the dimethylamino derivative as a white solid(10.81g).
To this compound (3.17g) was added a 4.0M solution of hydrochloric acid in dioxane (20mL) at room temperature. After stirring for 1 hour the volatiles were removed in vacuo to yield the desired title compound as a viscous oil (2.79g) A598140speci Reference Example 2G. (S)-2-Amino-3-dimethylamino-propan-1 -ol. Hydrochloride salt (111.7) N-[(tert-Butoxy)carbonyl]-O-(tert-butyldimethylsilyl)-R-serine methyl ester was prepared according to the literature Scheeren et al, J. Org. Chem. 1990, p3998) from D-serine methyl ester hydrochloride Treatment of this compound with diisobutyl aluminium hydride in toluene at -70C for 2 hours yielded the correponding aldehyde (H.W.
Scheeren et al, J. Org. Chem. 1990, p3998).
A mixture of the crude aldehyde(4.43g) ,dimethylamine.hydrochloride (2.26g), sodium cyanoborohydride (1.31g) and sodium acetate (1.83g) was stirred in methanol (55mL) for 24 hours at room temperature. Aqueous work-up yielded the dimethylamine derivative. This was dissolved in dioxane and to this was added a 4.0 M solution of hydrochloric acid in dioxane and the mixture stirred for 20 minutes. Concentration of the mixture in vacuo yielded the crude desired title compound as a white solid.
Reference Example 2H. 3(S)-Amino-4-dimethylamino-butan-2(S)-ol. Hydrochloride salt (111.8) Hydrogen chloride gas was bubbled through a solution of D-threonine (20g) in S methanol (50mL).. The resulting solution was stirred for 5 hours at room temperature and S then reduced in vacuo to yield D-threonine methyl ester hydrochloride as a white solid 20 (quantitative yield). Treatment with di-tert-butyl dicarbonate in acetonitrile with triethylamine yielded N-(tert-butoxycarbonyl)-D-threonine methyl ester. Treatment of this compound with tert-butyldimethylsilyl chloride in dichloromethane with imidazole yielded the corresponding TBDMS protected alcohol.
Treatment of this compound with diisobutyl aluminium hydride in toluene at -780 C .*25 for 4 hours yielded the corresponding aldehyde (prep see H.W. Scheeren et al, J. Org. Chem.
1990, p3998). Reductive amination was carried out as described in Reference Example 2G to yield the corresponding dimethylamino derivative. Deprotection using 4.0M HCI in dioxane as described in Reference Example 2G yielded the title compound as a golden oil.
Reference Example 21. 3-Amino-4-dimethylamino-butan-l-ol. Hydrochloride salt (111.9) DL-Homoserine was treated with hydrogen chloride gas in methanol to yield the corresponding lactone. Treatment with di-tert-butyl dicarbonate in acetonitrile with triethylamine yielded the N-tert-butoxycarbonyl protected derivative.
A5981 31 Treatment of this compound with diisobutyl aluminium hydride in toluene at -780 C for 4 hours yielded the corresponding lactol (prep see H.W. Scheeren et al, J. Org. Chem. 1990, p 3 9 9 8).
Reductive amination was carried out as described in Reference Example 2G to yield the corresponding dimethylamino derivative, 3-[N-(tert-Butoxycarbonyl)amino]-4dimethylamino-butan-1-ol. Deprotection using 4.0M HCI in dioxane as described in Reference Example 2G yielded the desired title compound.
Reference Example 2J. 1-Methyl-3-(R)-aminopyrrolidine. Hydrochloride salt (III. A solution of 3R-(-)-1-benzyl-3-aminopyrrolidine(commercially available, 847mg) in tert-butanol (10mL) and 1.ON sodium hydroxide solution (4.8mL) was treated dropwise with a solution of di-tert-butyl dicarbonate (1.06g) in tert-butanol (5mL). After 1.5 hours tertbutanol was removed in vacuo and the residue dissolved in ethyl acetate, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield the desired 3N-tert-butoxycarbonyl protected derivative as a colourless gum (1.26g).
A solution of the 3N-tert-butoxycarbonyl protected derivative (800mg) in tetrahydrofuran was stirred over palladium hydroxide catalyst under an atmosphere of hydrogen for 24 hours.
S The reaction mixture was then filtered through celite and the solvent removed in vacuo to S yield the desired 3N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine (quantitative yield).
20 To a solution of N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine (437mg) in methanol (OmL) was added 37% formaldehyde solution in H 2 0 (0.52mL) and sodium borohydride(271mg). The reaction mixture was stirred for 24 hours at room temperature and then reduced in vacuo. The residue was dissolved in chloroform, washed with brine and NaHCO 3 solution, dried (MgSO 4 and the solvent removed in vacuo to yield the desired 3Ntert-butoxycarbonyl-3-(R)-amino-l-methylpyrrolidine as a gum (390mg). Deprotection with 4.0M HCI solution in dioxane as described above yielded the desired title compound.
Reference Example 2K. N',N',N2-Tetramethyl-propane-l,2,3-triamine trihydrochloride (III.11) To ice cooled thionyl chloride 35 mL), 1,3-bis(dimethylamino)-propan-2-ol (4.91 g, 33.58 mmol, commercially available) was added dropwise over 45 mins with stirring. After the addition was complete the mixture was stirred for a further 4 h. Excess thionyl chloride was removed under reduced pressure to give 8.9 g of a cream solid of the product as the hydrochloride salt. The free base was obtained by treating a suspension of the hydrochloride AS8140spcci salt in toluene (18 mL) with sodium hydroxide (2.4 eq) in water (14 mL) for 30 min. The organic layer was removed, dried over MgSO 4 filtered and the solvent removed in vacuo to yield 2-chloro-N,N,N',N'-tetramethylpropane-1,3-diamine as a yellow liquid.
2-Chloro-N,N,N1,Nl-tetramethylpropane-1,3-diamine (1.6 g, 9.71 mmol) as a solution in toluene (14 mL) was treated with potassium phthalimide (1.98 g, 10.68 mmol). The stirred mixture was heated at reflux for 18 h under an inert atmosphere, cooled to ambient temperature and the solvent removed under reduced pressure to yield a beige solid, recrystallisation from diethyl ether afforded a fawn solid (1.85 This solid (0.953, 3.46 mmol) as a solution in ethanol (10 mL) was treated with hydrazine hydrate (0.22 mL, 6.93 mmol) and the mixture stirred at ambient temperature for 18 h. The suspension was removed by filtration and the filtrate acidified with 2 mL of2 M hydrochloric acid and the solvent removed in vacuo to give the product as a cream solid (795 mg). M.pt 126.5 128 oC, MH 432.
Reference Example 3 Preparation of Compounds of General Formula (IV) S Reference Example 3A. 4-Methoxy-benzo[a]phenazine- 1-carboxylic acid methyl ester Acetyl chloride (4.6mL) was added dropwise to a suspension of 4-methoxy- 20 benzo[a]phenazine-l 1-carboxylic acid (II.1,see Reference Example 1A, 4.9g) in methanol (50mL). The mixture was heated to reflux for 4 hours. The volatiles were then removed in vacuo to yield the title compound as a dark solid (quantitative yield).
NMR, d6-DMSO, 8.76(1H,d), 8.41(2H,d), 8.26(lH,d), 8.00(1H,t), 7.90(1H,d), 7.78(lH,t), 7.43(1H,d), 4.08(3H,s), 4.03(3H,s).
Reference Example 3B. Benzofalphenazine-11-carboxvlic acid methyl ester (IV.2) The mixture of benzo[a]phenazine- 11-carboxylic acid (11.20) and benzo[a]phenazine- 8-carboxylic acid (885mg), prepared as described in Reference Example 1L above, was heated to reflux in a mixture of methanol(40mL) and acetyl chloride(920p/L) for 90 minutes.
The reaction mixture was then cooled slowly to yield the title compound as a single isomer which was collected by filtration (377mg).
NMR, d6-DMSO, 9.53-9.55(lH,m), 9.06(1H,d), 8.57(IH,d), 8.47(1H,d), 8.35(1H,d), 8.10- 8. 1 8.09-8.02(1H,m), 7.95-8.01(2H,m), 4.21(3H,s) A59S140spOci 33 Reference Example 3C. 4-Dimethylamino-benzo[alphenazine- Il-carboxvlic acid methyl ester (IV.3) and 3-dimethylamino-benzoralphenazine- I1-carboxvlic acid methyl ester (V.4) To the 4:1 mixture of 4-amino-benzo[a]phenazine-1 I-carboxylic acid (11.29) and 3amino-benzo[a]phenazine- II -carboxylic acid (II.30)(48mg) in N,Ndimethylformamide(l OmL) from Reference Example IN was added methyl diisopropylethylamine (2.0mL). The reaction mixture was heated to 100 0
C
for 4 hours. The mixture was cooled, diluted with ethyl acetate, washed with water, dried (MgSO4) and the solvent removed in vacuo to yield the title compounds as a red solid (29mg). Purified after further chemical modification.
Reference Example 3D. 1 O-Fluoro-4-methoxy-benzora]phenazine- 11 -carboxylic acid methyl ester Methyl 2-amino-6-fluoro-3-nitrobenzoate was prepared according to the literature (J.
Med. Chem 1993, p2335). Hydrogenation over palladium on carbon in methanol yielded 2,3diamino-6-fluoro-benzoic acid methyl ester. This compound was reacted with [1,2]naphthoquinone in cold ethanol acid with concentrated HCI to yield the desired title compound.
Se: NMR, CDCI3, 4.08(3H,s), 4.20(3H,s), 7.20(1H,d), 7.65-7.75(2H,m), 7.92(1H,d), 8.35(lH,dd), 8.53(1H,d), 8.91(1H,d) :4 20 MS m/e 337 100%) Reference Example 3E. 4-Methoxy- 1 0-methylamino-benzora]phenazine- 11 -carboxylic acid methyl ester (IV.6) A mixture of 10-fluoro-4-methoxy-benzo[a]phenazine-11-carboxylic acid methyl 25 ester (IV.5) (100mg) and 2.0M solution of methylamine in tetrahydrofuran was stirred at room temperature for 18 hours. The solvent was then removed in vacuo to yield the crude desired title compound as an orange solid.
Reference Example 3F. 10-Amino-4-methoxy-benzo[alphenazine-11-carboxylic acid methyl ester (IV.7) A mixture of 10-fluoro-4-methoxy-benzo[a]phenazine- 11-carboxylic acid methyl ester (IV.5) (466mg) and sodium azide (900mg) in N,N-dimethylformamide(lOmL) was heated at 90C for 18 hours. The reaction mixture was then cooled, diluted with water, and then sodium hydroxide solution was added resulting in a brown precipitate. This was A 5914Ospmcc collected by filtration and washed with water and ether to yield the desired title compound as a yellow solid (242mg).
NMR, CDCl3, 4.08(3H,s), 4.20(3H,s), 7.25(1H,d), 7.70-7.72(2H,m), 7.90(1H,d), 8.36(1H,d), 8.52(1H,d), 8.85(1H,d).
MS DCI/NH3 m/z334(MH+,100%) Example 1: Preparation of Compounds of General Formula (I) Example 1A. 4-Methoxy-benzo[a]phenazine- 11l-carboxylic acid (2-dimethylamino-ethyl)amide A mixture of 4-methoxy-benzo[a]phenazine-11-carboxylic acid (11.1) (129mg) and 1,1'-carbonyldiimidazole(138mg) was stirred in dry N,N-dimethylformamide (8mL) at room temperature for 4 hours. To this mixture was added N,N-dimethylethylenediamine (commercially available)(0.5mL) and the reaction mixture was stirred at room temperature for a further 30 minutes. The volatiles were then removed in vacuo. The residue was dissolved in dichloromethane, washed with water, dried (MgSO 4 and the solvent removed in vacuo to provide crude product. This was purified using flash chromatography methanol in dichloromethane) to yield the title compound as a bright yellow solid (120mg).
The following compounds of formula were prepared in an analogous manner using the appropriate starting acid of formula (11) and amine of formula (III).
4-Nitro-benzo[a]phenazine-11-carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from the mixture of 4-nitro-benzo[a]phenazine- 11-carboxylic acid (11.27) and 3-nitrobenzo[a]phenazine-11-carboxylic acid (11.28), and N,N-dimethylethylenediamine and then purified using flash chromatography; 4-Benzyloxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-benzyloxy-benzo[a]phenazine- 11 -carboxylic acid (11.13) and N,Ndimethylethylenediamine; 4-Prop-2-ynyloxy-benzo[a]phenazine-11-carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-prop-2-ynyloxy-benzo[a]phenazine-11-carboxylic acid (II.14) and N,Ndimethylethylenediamine; 4-Ethoxy-benzo[a]phenazine- I I -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-ethoxy-benzo[a]phenazine-l l-carboxylic acid (11.11) and N,Ndime thylethylenediamine; A59140sjxc, 4- lsobutoxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-isobutoxy-benzola]phenazine-1 1-carboxylic acid (11.15) and N,Ndimethylethylenediamine; 4.-(4-Chloro-benzyloxy)-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)amide was prepared from 4-(4-chloro-benzyloxy)-benzoI~a]phenazine-1 1-carboxylic acid (11. 16) and N,N-dimethylethylenediamine; 4-(2-Methoxy-ethoxy)-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)amide was prepared from 4-(2-methoxy-ethoxy)-benzoI~a]phenazine-1 1-carboxylic acid (11. 17) and N,N-dimethylethylenediamine; [1 1 (2-Dimethylamino-ethylcarbamoyI)-benzo[a]phenazil-4-yloxy] -acetic acid ethyl ester was prepared from 4-ethoxycarbonylmethoxy-benzo[a]phenazine- II-carboxylic acid (11. 18) and N,N-dimethylethylenediamine; 4-[2-(tert-Butyl-dimethy-silanyloxy)-ethoxy]-belzo[a]phelazife- 11 -carboxylic acid (2dimethylamino-ethyl)-amide was prepared from 4-[2-(tert-butyl-dimethyl-silalyloxy)ethoxy] -benzo[a]phenazine- II-carboxylic acid (11. 19) and N,N-dimethylethylenediamine; 4-M ethyl -benzo phenazine- I11 -carboxylic acid(2-dimethylamino-ethyl)-amide was prepared from 4-methyl-benzo[a]phenazine- II-carboxylic acid (11.2) and N,Ndimethylethylenediamine; 4-Fluoro-benzo[a]phenazine- 11I -carboxylic acid(2-dimethylamino-ethyl)-amide was prepared 20 from 4-fluoro-benzo[a]phenazine- II-carboxylic acid (11.3) and N,Ndimethylethylenediamine; 4-Methylsul fanyl-benzo[alphenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-methylsulfanyl-benzo[a]phenazine-1 1-carboxylic acid (11.12) and N,Ndimethylethylenediamine; 4-Bronio-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-bromo-benzo[a]phenazine-1 I1-carboxylic acid (11.5) and N,Ndirnethylethylenediamine; :4-Cyano-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-arnide was prepared from 4-cyano-benzolla]phenazine- II-carboxylic acid (11.6) and N,Ndirnmethylethylened iami ne; A 50S 1 4 Ospmc 36 4-Methanesulfonyl-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-methanesulphonyl-benzo[a]phenazine-1 I1-carboxylic acid (11.8) and N,N-dimiethylethylenediamine; 4-Chloro-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-chloro-benzo[a]phenazine- II-carboxylic acid (11.7) and N,Nd imrethyl ethyl ened iamine; 4-Azido-benzo[a]phenazine- I11 -carboxylic acid(2-dimethylamino-ethyl)-amide was prepared from 4-azido-benzo[a]phenazine- II-carboxylic acid (11.9) and N,Nd imrethyl ethyl enedi am ine; I1-(2-Dimethylamino-ethylcarbamoyl)-benzo[a]phenazine-4carboxylic acid methyl ester was prepared from benzo[a]phenazine-4,1 I1-dicarboxylic acid 4methyl cster (11. 10) and N,N-di methyl ethyl enedi amine; 4-Methylsulfamoyl-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide; trifluoro-acetate was prepared from the mixture of 4-methylsulfamoyl-benzo[a]phenazine-1 1carboxylic acid (11.21 )and 3 -methylsul famoyl-benzo[a]phenazine- I1 -carboxylic acid(IL.22), 1 5 and N,N-dimethylethylenediamine. The two isomers were separated using preparative HPLC; 4-Dimethylsulfamoyl-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prcpared from the mixture of 4-dimethylsulfamoyl-benzo[a]phenazine-1 1-carboxylic acid (II.23)and 3-dimethylsulfamoyl-benzo[ajphenazine-1 1-carboxylic acid (11.24), and N,Ndimethylethylenediamine. The two isomers were separated using flash chromatography; 9-Bromo-4-methoxy-benzo[alphenazine-I 11-carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 9-bromo-4-methoxy-benzo[a]phenazine- II-carboxylic acid (11.35) and N,N-dimethylethylenediamine; 4-Nitro-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino- 1 -m ethyl -ethyl) -ami de was prepared from the mixture of 4-ni'tro-benzo[a]phenazine-1 1-carboxylic acid (11.27) and 3- .:25 nitro-benzo[a]phenazine-I 1-carboxylic acid (11.28), and I-dimethylamino-2-propylamine, and then purified using flash chromatography.
Example l B. 4-Methoxy-benzoralphenazine-1 1-carboxylic acid (2-dimethylamino-li-nthyl-ethyl)-amide A mixture of 4-methoxy-benzo[a]phenazinc- II-carboxylic acid methyl ester (IV. 1) (350mg) and I -dimethylamino-2-propylamine(2m L)(commercial ly available) was heated to I1 I0 0 C under N 2 for 4 hours. The reaction mixture was then cooled and the excess amine was removed in vacuo. The residue was then purified using flash chromatography (silica, ethyl I A0st-c acetate and then 25% methanol in ethyl acetate) to yield the title compound as a yellow solid (I164mg) The following compounds of formula were prepared in an analogous manner using the appropriate starting ester of formnula (IV) and the appropriate amine of Formnula (11l): 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (3-dimethylamino-propyl)-amide was prepared from 4-methoxy-benzo[a]phenazine- II-carboxylic acid methyl ester (IV. 1) and 3- (dimethylamino) propylamine(commercially available); 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (3-amino-2-hydroxy-propyl)-amide was prepared from 4-methoxy-benzo[a]phenazine-1 1-carboxylic acid methyl ester (IVAl) and 1,3diamino-2-hydroxypropane (commercially available); 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-propyl)-amide was prepared from 4-methoxy-benzo[a]phenazine- II-carboxylic acid methyl ester (IV. 1) and N 2 ,N 2 -dimethylpropane-I ,2-diamine (commercially available); 4-Dimethylamino-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from the mixture of 4-di1m ethyl amino-benzo phenazine- II-carboxylic acid methyl ester (IV.3) and 3-dimethylamino-benzo[a]phenazine- II-carboxylic acid methyl ester (IVA4), and N,N-dimethylethylenediamine, followed by flash chromatography purification to remove the minor isomer; 4-Methoxy- I 0-methylamino-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)- 9.amide was prepared from 4-methoxy-1IO-methylamino-benzo[a]phenazine- I I-carboxylic acid :9methyl ester (IV.6) and N,N-d imeth yl ethyl enedi amine; I 0-Amino-4-methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-di methyl am ino-ethyl)-ami1de was prepared from l0-amino-4-methoxy-benzo[a]phenazine-1 1-carboxylic acid methyl ester (IV.7 and N,N-dimethylethylenediamine; and 4-Methoxy-benzo[a]phenazine- 11I -carboxylic acid (2-m ethyl am ino -ethyl)- ami de was prepared from 4-methoxy-benzo[a]phenazine- I I-carboxylic acid methyl ester (IV. I) and N- 99 **tyendimie Example I C. 4-Methoxy-benzofalphenazine-1 1-carboxylic acid (2-dimethylamino-],ld im ethyl -ethyl)-ami d A mixture o~f 4-methoxy-benzo[a]phenazine-l 1-carboxylic acid (IL.1) and thionyl chloride was heated to reflux for 6 minutes. Thionyl chloride was then removed in vacuo.
The residue was dissolved in dry dichloromethane at 0 0 C and 1-diniethylamino-2-methyl-2- A 599I aminopropane (commercially available) was added. After stirring for 2 hours the reaction mixture was dissolved in dichloromethane, washed with sodium bicarbonate solution, dried (MgSO 4 and the solvent removed in vacuo to provide crude product. This was puri fied using flash chromatography to yield the title compound.
The following compounds of formula were prepared in an analogous manner using the appropriate starting acid of formnula (II) and the appropriate amine of Formnula (III) 4,1 O-Dimiethoxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4,1 O-dimethoxy-benzo[a]phenazine- 11 -carboxylic acid(II.36) and N,Ndimethylethylenediamine; 4-Methoxy-8-methyl-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared from 4-methoxy-8-methyl-benzo[a]phenazine-1 1-carboxylic acid (11.37) and N,N-dimethylethylenediamine; 9-Chloro-4-methoxy-benzo[a]phenazine- I1I -carboxylic acid (2-dim ethyl amino-ethyl) -am ide was prepared from 9-chloro-4-methoxy-benzo[a]phenazine-l 1-carboxylic acid (11.38) and N,N-dimethylethylenediamine; 4,1 0-Dimethoxy-benzo~a]phenazine- 1-carboxylic acid (2-dimethylamino- I -methyl-ethyl)aide was prepared from 4,1l0-dimethoxy-benzo[a]phenazine- II-carboxylic acid (11.36) and 1 -dimethylamino-2-propylamine(comm-ercially available); 4-Methoxy-benzo[a]phenazine- I1-carboxylic acid (1 -dimethyl aminomethyl -prop yl)-amide was prepared from 4-methoxy-benzo~~a]phenazine-1 1-carboxylic acid (11.1) and di methyl -butane-1I,2-diamine.hydrochloride (111.2) in the presence of triethylamine; 4-Methoxy-benzo[a]phenazine-I 1-carboxylic acid (1 -dimethylaminomethyl-2-methylpropyl)-amide was prepared from 4-methoxy-benzo[a]phenazine-1 1-carboxylic acid (11.1) and 3N ,N -tri methyl -butane-l,2-di amine. Hydrochloride salt (111.3) in the presence of triethylamine; ::4-Methoxy-benzojla]phenazine-I 1-carboxylic acid (1 -d imethyl am inomethyl -2 -phen yl -ethyl)namide was prepared from 4-methoxy-benzo[a]phenazine-1 1-carboxylic acid (11.1) and dimethyl-3-phenyl-propane- 1,2-diamneHydrochloride salt (111.4) in the presence of triethylamine; 30 4-Methoxy-benzolla]phenazine-l 1-carboxylic acid (2-dimethyl am ino-1I-(S)-methyl -ethyl)amide was prepared from 4-rnethoxy-benzo[a]phenazine-lI 1-carboxylic acid (11.1) and N',N1 -dirnmethyl -propane-1,2-diamine.Flydrochloride salt (111.5) in the presence of tri ethyl am ine; A9I40spci 39 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethyl amino- I1(R)-methyl -ethyl)amide was prepared from 4-methoxy-benzo[a]phenazine- II-carboxylic acid (11. 1) and N 1,N' -dimethyl-propane- 1 ,2-diamine. Hydrochloride salt (111.6) in the presence of triethylamine; 4-Methoxy-benzolla]phenazine- 11 -carboxylic acid (2-dimethylamino- I (S)-hydrox ymnethylethyl)-amide was prepared from 4-methoxy-benzo[alphe~nazine-l 1-carboxylic acid (11.1) and (S)-2-Amino-3-dimethylamino-propan- I -ol.Hydrochloride salt (111.7) in the presence of triethylamine; 4-Methoxy-benzo[alphenazine- 11 -carboxylic acid (I (S)-dimethylaminomethyl- 2 hydroxy-propyl)-amide was prepared from 4-methoxy-benzo[a]phenazifle- II-carboxylic acid (11. 1) and 3(S)-Amino-4-dimethylamino-butan-2(S)-ol. Hydrochloride salt (111.8) in the presence of triethylamine; 4-Methoxy-benzoI~a]phenazine- 11I -carboxylic acid I -dimethylamino- 1 -(2-hydroxyethyl)]ethylamide was prepared from 4-methoxy-benzo[a]phenazifle- II-carboxyl ic acid (11. 1) and 3-Amino-4-dimethylamino-butan- I-ol. Hydrochloride salt (111.9) in the presence of triethylamine; 4-Methoxy-benzo~Ia]phenazine-I 1-carboxylic acid (2-piperidin- 1 -yl -ethyl)- amide was prepared from 4-methoxy-benzo[a]phenazine-1 1-carboxylic acid (11.1) and 1-(2aminoethyl)piperidine (commercially available); ~.20 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (2-morphol11n-4-yl -ethyl)- ami de wvas prepared from 4-methoxy-benzoI~a]phenazine-l 1-carboxylic acid (11.1) and 4-(2- 9* aminoethyl)morpholine (commercially available); 4-M ethoxy-benzolphenazine-I I-carboxylic acid (2-pyrrolidin-1I-yi-ethyl)-amide was 3 prepared from 4-methoxy-benzo[a]phenazine- II-carboxylic acid (11.1) and I- ::25 (amiinoethyl)pyrrolidine (commercially available); *4-M ethoxy-benzo[a]phenazine- I11 -carboxylic acid (2-diethylamino-ethyl)-amide was 2. prepared from 4-methoxy-benzo~a]phenazine- 11 -carboxylic acid (11.1) and N,Ndiethylethylenediamine (commercially available); 4-Methoxy-benzoj~a]phenazine- 11 -carboxylic acid (2 2[bis-(2-hydrox y-ethyl)-ami no]I-ethyl}see-.
30 amide was prepared from 4-rnethoxy-benzo[a]phenazine-I1I-carboxylic acid (11. 1) and N,Nbis(2-hydroxyethyl)ethylenediamine (commercially available); 4,1 0-Diniethoxy-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-1 h ydrox ymnethyl -ethyl)-amide was prepared from 4,1 0-dimethoxy-benzoI~a]phenazine- 11 A 598 1OSPMC carboxylic acid (11.36) and (S)-2-amino-3-dimethylamino-propafl1-ol.Hydrochloride salt (111.7) in the presence of aqueous sodium carbonate; 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (1 -methyl-pyrrolidin-3-(R)-yl)-amide was prepared from 4-methoxy-benzo~ja]phenazine- II-carboxylic acid (11. 1) and I1-methyl-3-(R)aminopyrrolidine. Hydrochloride salt (111. 10) in the presence of triethylamine; (R)-4-Methoxy-benzo[alphenazine- 11I -carboxylic acid( I -dimethylaminomethyl-2-methylpropyl)-amide was prepared from 4-methoxy-benzola]phenazine- II-carboxylic acid (11. 1) and -tri methyl -butane-l1, 2-diamine. Hydrochloride salt (III.3.a) in the presence of triethylamine; trihydrochloride(II1.1 11) in the presence of triethylamine; 4-Methoxy-benzo[a]phenazine- I11 -carboxylic acid (2,3-bis)-dimethylamino-propyl)amide was prepared from 4-methoxy-benzo[a]phenazine- II-carboxylic acid (11. 1) and N',N,N',N 2 tetramethyl -propane- I ,2,3-triamine.
Example 2: Interconversion of compounds of Formula (1) Compounds of Formula prepared as described in Example I were converted into other compounds of Formula as described below.
Example 2i. 4-Hydroxy-benzora]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)amide: hydrobromide salt To a solution of 4-methoxy-benzo[alphenazine- I I -carboxylic acid (2-dimethylaminoethyl)-amide 1) (727mg) in dry dichloromethane (Il5mL) cooled to -5OC was added a 1.OM solution of boron tribromide in dichloromethane (13.6mL). After stirring for 4 hours the reaction mixture was poured onto ice/water yielding a precipitate which was collected by filtration. This was triturated from a hot methanol/ethyl acetate mixture to yield the title compound as a beige solid (505mg).
Example 2i i. 4Cyanomethoxy-benzora]phenazine- I I -carboxylic acid (2-diiethylamlinoethyl')-a ide To a suspension of 4-hydroxy-benzo[a]phenazine-l 1-carboxylic acid (2dimiethylamino-ethyl)-amide: hydrobromide salt(230mg) in dry N,Ndi methyl formamide(3mL-) was added potassium lert-butox ide (I 75mg) and then A 5Q8140spmC 41 bromoacetonitrile(47lL). The reaction mixture was heated to 100 0 C for 1 hour. The reaction mixture was then cooled, diluted with ethyl acetate, washed with sodium carbonate solution and brine, dried (MgSO 4 and the solvent removed in vacuo to provide crude product. This was purified using flash chromatography (silica, 25% MeOH in ethyl acetate) to yield the title compound as a yellow solid (74mg).
The following compounds of formula were prepared in an analogous manner using 4-hydroxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)amide:hydrobromide salt and the appropriate alkylating reagent; 4-(Pyrimidin-2-yloxy)-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared using 2-bromopyridine; 4-(2-Morpholin-4-yl-ethoxy)-benzo[a]phenazine-l -carboxylic acid (2-dimethylaminoethyl)-amide was prepared using N-(2-chloroethyl)morpholine hydrochloride; 4-(3-Cyano-propoxy)-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared using 4-bromobutyronitrile; 4-(3-Dimethylamino-propoxy)-benzo[a]phenazine-11-carboxylic acid (2-dimethylaminoethyl)-amide was prepared using 3-dimethylaminopropyl chloride hydrochloride; 4-Carbamoylmethoxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared using 2-bromoacetamide; 4-(2-Oxo-propoxy)-benzo[a]phenazine-11-carboxylic acid (2-dimethylamino-ethyl)-amide 20 was prepared using chloroacetone; and [11 -(2-Di m ethylamino-ethylcarbamoyl)-benzo[a]phenazin-4-yloxy] -acetic acid tert-butyl ester was prepared using tert-butyl bromoacetate.
Example 2iii. Ethyl-carbamic acid 11 -(2-dimethylamino-ethylcarbamoyl)-benzofa]phenazin- 4-yl ester.
A mixture of 4-hydroxy-benzo[a]phenazine-11-carboxylic acid (2-dimethylaminoethyl)-amide: hydrobromide salt(540mg), triethylamine (0.51lmL) and ethyl isocyanate (0.29mL) was stirred in dry N,N-dimethylformamide(3mL). The product slowly precipitated from the reaction mixture and was collected by filtration and washed with ether to yield the title compound as a yellow solid (210mg).
A5s91SI40pc Example 2iv. Acetic acid 11 -(2-dimethylamino-ethylcarbamovl)-benzoralphenazin-4-yl ester A mixture of 4-hydroxy-benzo[a]phenazine-11-carboxylic acid (2-dimethylaminoethyl)-amide: hydrobromide salt(45mg), triethylamine (71zL) and acetyl chloride(20tL) in dichloromethane(1.4mL) was stirred at room temperature for 2 hours. All volatiles were removed in vacuo and the residue was purified using column chromatography (10% methanol in dichloromethane) to yield the title compound as a yellow solid (27mg).
Example 2v. r 1 -(2-Dimethylamino-ethylcarbamoyl)-benzoralphenazin-4-yloxyl-acetic acid trifluoroacetate salt To a solution of [11-(2-dimethylamino-ethylcarbamoyl)-benzo[a]phenazin-4-yloxy]acetic acid tert-butyl ester (18mg) in dry dichloromethane (ImL) was added trifluoroacetic acid (lmL). After stirring for 4 hours the solvent was removed in vacuo to yield crude product. This was triturated with ether to yield the title compound as a yellow solid Example 2vi. Benzo ra]phenazine-4, 1 -dicarboxylic acid 4-amide 11 -r(2-dimethylamineethyl)-amidel; triflouroacetic acid salt 11 -(2-Dimethylamino-ethylcarbamoyl)-benzo[a]phenazine-4-carboxylic acid methyl S ester (200mg) was sonicated in methanol(20mL) to give a fine suspension. To this was added 20 sodium cyanide (22mg). The mixture was then sparged with anhydrous ammonia for mins. The reaction mixture was stirred at room temperature for 10 days and on each day the mixture was sparged with ammonia. After 10 days the volatiles were removed in vacuo and the residue was purified using flash chromatography to yield crude product. This was further purified using preparative HPLC (isocratic; 80:20 H 2 0/acetonitrile) to yield the title compound as a yellow solid Example 2vii. 11 -(2-Dimethylamino-ethylcarbamovl)-benzora]phenazine-4-carboxylic acid, trifluoroacetate salt ll-(2-Dimethylamino-ethylcarbamoyl)-benzo[a]phenazine-4-carboxylic acid methyl ester (200mg) was sonicated in a mixture of methanol (4mL) and ammonium The suspension was then heated to 50 0 C for 92 hours. All volatiles were then removed in vacuo to yield crude product, which was purified using preparative HPLC to yield the title compound A5RI98140speci Example 2viii. 4-Hydroxymethyl-benzoralphenazine-1 1-carboxylic acid (2dimethylamino-ethyl)-amide To a solution of I11 -(2-di methyl am ino-ethylcarbamo yl)-benzo phenazi ne-4carboxylic acid methyl ester (317mg) in tetrahydrofuran (l8mL-) and 2-propanol (lOmL)at 0 0 C was added lithium borohydride (2.0M solution in tetrahydrofuran, I .97mL) The reaction mixture was stirred at room temperature overnight, and then quenched with ammonium chloride solution. The reaction mixture was extracted with ethyl acetate, dried (MgSO 4 and concentrated in vacuc. The residue was purified using flash chromatography (10% MeGH in dichloromethane) to yield the title compound as a yellow solid (98mg).
Example 2ix. 4-(N-Hydroxycarbamimidoyl)-benzoralphenazine- 11 -carboxylic acid (2dimethylamino-ethyl)-amide A mixture of 4-cyano-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylaminoethyl)-amide (20mg) potassium carbonate(37mg) and hydroxylamine hydrochloride(l9mg) was heated to reflux in ethanol (5mL) for 18 hours. The reaction mixture was filtered, and the 1 5 filtrate was collected and the solvent removed in vacuo to Yield the title compound :Example 2x. 4-Dimethylaminomethyl-3 -hydroxy-benzoralphenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 3-Hydroxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide (26mg) was sonicated in acetic acid (2mL) to give a fine suspension. To this was added a solution of dimethylamine in water (3niL) and a 37% solution of formaldehyde in water (3mL). The reaction mixture was left stirring for 2 days. The volatiles were then removed in vacuc to Yield the title compound (29mg).
3-Dinmethylaminomethyl-4-hydroxy-benzo[a]phenazine- I11 -carboxyl ic acid (2dirnethylamino-ethyl)-amide was prepared in an analogous manner from 4-hydroxybenzo[a]phenazine- II-carboxylic acid (2-dimethylamino-ethyl)-amide.
Example 2xi. 4-(2-Hydroxy-ethoxy)-benzoralphenazine-I 1-carboxylic acid (2d i methyl arnino-eth yl)-amide To a solution of 4-[2-(tert-butyl-dimethyl-si lanyloxy)-ethoxy] -benzo[a]phenazine-I I1carboxylic acid (2-dimethylamitno-ethyl)-amide (125mg) in tetrahydrofuran(5mL) was added a I OM solution of tetrabutyl ammonium fluoride (I .2mL). After stirring for 1.5 hours the reaction mixture was diluted with ethyl acetate, washed with water, dried (MgSO 4 and the A598140speci 44 solvent removed in vacuo to yield crude product which was purified using flash chromatography to yield the title compound as an orange solid (24mg).
Example 2xii. 4-Amino-benzo[alphenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)amide A mixture of 4-nitro-benzo[a]phenazine-l l-carboxylic acid (2-dimethylamino-ethyl)amide(176mg), indium(154mg) and saturated ammonium chloride solution (5mL) in was heated to reflux for 3 hours. The reaction mixture was cooled, quenched with water and then filtered through celite. The filtrate was concentrated in vacuo, and the residue was treated with sodium bicarbonate solution, extracted into chloroform, dried (MgSO 4 and the solvent removed in vacuo to yield the title compound as a red solid (163mg) 3-Amino-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide was prepared in an analogous manner from 3-nitro-benzo[a]phenazine-l 1-carboxylic acid (2dimethylamino-ethyl)-amide.
Example 2xiii. 4-Acetylamino-benzo[alphenazine- 1 I-carboxylic acid (2-dimethylaminoethyl)-amide To a solution of 4-amino-benzo[a]phenazine-ll-carboxylic acid (2-dimethylamino- S 20 ethyl)-amide(20mg) in tetrahydrofuran(5mL) was added pyridine(0.lmL) and acetyl After stirring for 1 hour the reaction mixture was extracted into ethyl acetate, washed with sodium bicarbonate solution, dried (MgSO 4 and the solvent removed in vacuo.
S. The residue was triturated with ether to yield the title compound as a yellow solid 3-Acetylamino-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)- 25 amide was prepared in an analogous manner from 3-amino-benzo[a]phenazine- 1-carboxylic acid (2-dimethylamino-ethyl)-amide and acetyl chloride; 4-Methanesulfonylamino-benzo[a]phenazine-11-carboxylic acid (2-dimethylamino-ethyl)amide was prepared in an analogous manner from 4-amino-benzo[a]phenazine- I1-carboxylic acid (2-dimethylamino-ethyl)-amide and methanesulphonyl chloride; 3-Methanesulfonylamino-benzo[a]phenazine- 11-carboxylic acid (2-dimethylamino-ethyl)amide was prepared in an analogous manner from 3-amino-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide and methanesulphonyl chloride; 4-Bis-(Methanesulfonylamino)-benzo[a]phenazine-11-carboxylic acid (2-dimethylaminoethyl)-amide was prepared in a similar manner from 4-amino-benzo[a]phenlazine- 11- A598140spec.
carboxylic acid (2-dimethylamino-ethyl)-amide using excess methanesulphonyl chloride, and triethylamine as base.
Example 2xiv. 4-(Cvanomethyl-amino)-benzo[a]phenazine- 11-carboxylic acid (2dimethylamino-ethyl)-amide To a solution of 4-amino-benzo[a]phenazine-11-carboxylic acid (2-dimethylaminoethyl)-amide(69mg) in methanol (O10mL) was added formaldehyde (37% solution, 1.OmL), potassium cyanide(102mg)and 2N HCI (1.OmL). The reaction mixture was heated to 50 0 C for 3 hours. The reaction mixture was then cooled, diluted with water and sodium bicarbonate solution, extracted into dichloromethane, dried (MgSO 4 and the solvent removed in vacuo to yield crude product. This was purified using flash chromatography (10% methanol in dichloromethane) to yield the title compound as a violet coloured solid (13mg) Example 2xv. 4,1 0-Dihydroxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylaminoethyl)-amide To a cold solution of 4,10-dimethoxy-benzo[a]phenazine-l l-carboxylic acid (2dimethylamino-ethyl)-amide (96mg) in dichloromethane(2mL)was added a 1.OM solution of boron tribromide in dichloromethane (2.14mL, 9 equivalents). The reaction mixture was stirred for 16 hours and then ice was added with sodium carbonate and sodium chloride. The 20 organics were extracted into dichloromethane, dried (MgSO4), and the solvent removed in Svacuo to yield an orange compound which was recrystallised from dichloromethane/methanol/hexane to yield the title compound (6mg).
S Example 2xvi. 10-Hydroxy-4-methoxy-benzo[alphenazine- 11-carboxylic acid (2- 25 dimethylamino-ethyl)-amide To a cold solution of 4,10-dimethoxy-benzo[a]phenazine-11-carboxylic acid (2dimethylamino-ethyl)-amide (300mg) in dichloromethane (25mL) was added a 1.OM solution of boron tribromide in dichloromethane (1.63mL, 2.2 equivalents). The reaction mixture was stirred for 6 hours and then ice was added with sodium carbonate and sodium chloride. The organics were extracted into dichloromethane, dried (MgSO4), and the solvent removed in vacuo to yield a yellow solid which was purified using flash chromatography to yield the title compound (61mg) A5Qs8 140spcci 1 0-Hydroxy-4-methoxy-benzo[a]phenazine- Il -carboxylic acid (2-dimethylamino- I (R)-methyl-ethyl)-amide was prepared in an analogous manner from 4,1 0-dimethoxybenzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-l (R)-methyl-ethyl)-amide; and I 0-Hydroxy-4-methoxy-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-l hydroxymethyl-ethyl)-amide was prepared in an analogous manner from 4,10 O-dimethoxybenzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-l (S)-hydroxymethyl-ethyl)-amide.
Example 2xvii. 4-Methoxy-9-methylsulfanyl-benzoralphenazine- 11 -carboxylic acid (2dimethylamino-ethyl)-amide A mixture of 9-chloro-4-methoxy-benzo[a]phenazine-1I1-carboxylic acid (2dimethylamino-ethyl)-amide(85mg) and sodium thiomethoxide (43mg) in N,Ndimethylformamide (ImL) was heated to 120 0 C for 6 hours and 60'C for 16 hours. The reaction mixture was then cooled, diluted with ethyl acetate, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield a yellow solid which was purified using flash chromatography to yield the desired title compound (37mg).
Example 2xviii. 4,9-Dimethoxy-benzo[a]phenazine- Il -carboxvlic acid (2dimethylamino-ethyl)-amide A mixture of 9-chloro-4-methoxy-benzo[a]phenazine-1 -carboxylic acid (2and a 25% solution of sodium methoxide in methanol(4mL) was heated to reflux for 6 hours. The reaction mixture was then cooled, diluted with ethyl acetate, washed with water, dried (MgSO 4 and the solvent removed in vacuo to yield a yellow solid which was purified using flash chromatography to yield the desired title compound (42mg).
Example 2xix. 4-Methoxy-benzo[a]phenazine- Il-carboxvlic acid (2-dimethylamino-l- '..025 hydrox ymethyl-ethyl)-amide A mixture of 3-dimethylamino-2-[(4-methoxy-benzo[a]phenazine- 1 I-carbonyl)amino]-propionic acid methyl ester(335mg) and lithium borohydride(72mg)in tetrahydrofuran (l0 OmL) and isopropanol (IOmL) was stirred at room temperature for 18 hours. Another 5 equivalents of lithium borohydride were added and the mixture stirred for another 18 hours. The reaction was quenched with ammonium chloride solution and extracted with ethyl acetate, dried (MgSO 4 and the solvent removed in vacuo to yield a A598140lOpcci 47 brown gum. Purification using flash chromatography and trituration with ether yielded the desired title compound as an orange powder.
Example 3: Biological testin2 of compounds of formula (I) The cytotoxicity of compounds of formula was measured using the H69 parental (H69/P) human small cell lung carcinoma cell line and the drug resistant human small cell lung carcinoma cell line H69/LX4 which overexpresses P-glycoprotein (Pgp). The cytotoxicity, as measured by the IC5o (concentration required to give 50% cell kill) in the H69/LX4 cell line divided by the cytotoxicity in the H69/P cell line gives an indication of the degree to which a compound is affected by Pgp-dependent MDR and is termed the resistance factor (Rf) of the compound.
H69/P and H69/LX4 cells were pipetted into 96-well tissue culture plates and then allowed to incubate at 37 0 C for 4 h. A range of concentrations from 0.01 nM to 5pM of compounds of formula or the standards TAS-103, Doxorubicin and Topotecan were then added. The plates were incubated for 5-6 days before adding AlamarBlue to each well and returning the plates to the incubator for 5-8 h to allow colour development. The cell numbers in the plates at the end of this period were directly proportional to the absorbance measured at a wavelength of 570 nm (reference wavelength 600 nm).
The compounds of formula were active in the range 5 nM to 5 IM. Specific results 20 for selected compounds are listed in table 1.
*CCC
*e ee« ee A59S140spci 48 Table 1.
Compound H69/P IC5o(nM) H69/LX4 IC5o(nM) Rf TAS-103 21 22 1.1 Doxorubicin 27.3 3700 135 Topotecan 15.9 61.5 3.9 4 35 48 1.4 3 35 49 1.4 11 28 24 0.9 94 19 25 1.3 68 19 25 1.3 23 28 1.2 81 20 25 1.2 78 24 31 1.3 98 21 20 1 84 19 19 1 *4S*
S
4 SA S S
S.
4
S
S S 54 5 S S
A
5.5.
S
A
S
54-
S
I 9840spccs 49 The cytotoxicity of the compounds described herein was also measured using the COR-L23 parental (COR-L23/P) human non-small cell lung carcinoma cell line and also the drug resistant human non-small cell lung carcinoma cell line COR-L23/R which overexpresses multidrug resistance associated protein (MRP). The cytotoxicity, as measured by the IC 50 (concentration required to give 50% cell kill) in the L23/R cell line divided by the cytotoxicity in the L23/P cell line gives an indication of the degree to which a compound may be affected by MRP-dependant MDR and is termed the resistance factor (Rf) of the compound.
L23/P and L23/R cells were pipetted into 96-well tissue culture plates and then allowed to incubate at 37 0 C for 4 h. A range of concentrations from 0.0lnM to 5pM of compounds of formula or the standards TAS-103, Doxorubicin and Topotecan were then added. The plates were incubated for 5-6 days before proliferation was assessed using the sulphurhodamine B (SRB) assay as described by Skehan et al, J Natl Cancer Inst 1990, 82, pp1107-1112.
Compounds were active in the range InM to 5AM. Specific examples are listed in Table 2.
oo*** oooo* **g A598140pcc Table 2.
Compound L23/P ICso(nM) L23/R ICso(nM) Rf TAS-103 16.3 22 1.3 Doxorubicin 20.3 326.8 16.1 Topotecan 13.6 20.8 4 14.7 16.8 1.1 3 14.4 19.9 1.4 11 6.1 17.7 2.9 94 5.7 3.8 0.7 68 13.1 44.4 3.4 75 13.0 17.2 1.3 81 4 12.4 3.1 78 7.6 8.9 1.2 98 9.6 8.8 0.9 The cytotoxicity of the compounds described herein was also measured using the Jurkat human leukaemia cell line (JLc) and also the amsacrine-resistant Jurkat human 5 leukaemia cell line (JLA) and the doxorubicin-resistant Jurkat human leukaemia cell line (JLD). The cytotoxicity, as measured by the ICso 0 (concentration required to give 50% cell kill) in the JLA or JLD cell line divided by the cytotoxicity in the JLc cell line gives an indication of the degree to which a compound may be affected by atypical drug resistance and is termed the resistance factor (Rf) of the compound. The method used has been described previously (Finlay et al, Eur J. Cancer 32A, 708-714, 1996). Compounds were active in the range InM to 5pM. Specific examples are listed in Table 3.
A59S 140s 1 c, Table 3.
Compound JLc ICso(nM) JLA ICso(nM) Rf(JLA/JLc) JLD ICso(nM) Rf(JLD/JLc) TAS-103 5.4 302 55.9 384 71.1 Doxorubicin 7.0 25.9 3.7 109 15.6 4 19.0 26.6 1.4 22.8 1.2 3 27.0 21.6 0.8 24.3 0.9 2 37 96 2.6 107 2.9 28 19 0.7 25 0.9 78 21 14 0.7 17 0.8 81 8.7 9.2 1.1 9.3 1.1 84 4.4 9.8 2.2 7.2 1.6 87 16 16 1.0 17 94 9.2 16 1.8 14 1.6 98 8.6 18 2.1 14 1.6 Compounds were also studied for their ability to stabilize cleavable complexes in the presence of either topoisomerase I or II essentially as described previously (Finlay et al, Eur J. Cancer 32A, 708-714, 1996). Presence of cleavable complexes was indicated by an increase in the number and intensity of bands observed after electrophoresis and autoradiography. The results are expressed as the effective concentration range where an increase in cleavable complexes was observed relative to controls in the absence of drug. A A598140spcc1 52 number of compounds described herein were tested using these protocols and compounds showed poisoning of topoisomerases I and II in the range 0.01 20 pM. Specific examples are listed in Table 4.
Table 4 Effective concentration range (pM) Compound Topoisomerase I Topoisomerase II TAS-103 0.3-10.0 0.3-10.0 3 0.1-3.0 0.1-3.0 4 0.1-3.0 0.1-3.0 0.03-1.0 0.03-1.0 78 0.03-1.0 0.03-1.0 84 0.03-1.0 0.03-1.0 Example 4: Pharmaceutical composition ooeo m 0 2 15 o oo o o ooooo* o o Tablets, each weighing 0.15 g and containing 25 mg of a compound of the invention can be manufactured as follows: Composition for 10,000 tablets Compound of the invention (250g) lactose (800 g) corn starch (415 g) talc powder (30 g) magnesium stearate (5 g) The compound of the invention, lactose and half of the corn starch are mixed. The mixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml). The resulting paste is used to granulate the powder. The granulate is dried and broken up into small fragments on a sieve of 1.4 mm mesh size. The remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
A 58140speci 53 Example 5: Characterisation of compounds of formula (1) The compounds prepared in Examples 1 and 2 were characterised by proton N.M.R.
spectroscopy and mass spectrometry. All proton NMR was performed at 400 MHz.
Characterisation by mass spectrometry was performed using desorption chemical ionisation or electrospray ionisation. The results are set out in the following Table.
AS598140spccl COMPOund Molecular Mass spec 'H N.M.R. data Number Formula data 3 C22H22N402 MH+ 375 1 0.27(br, 1 H),8.96(d,J=8. 19Hz, 1 H),8.7 1 (dd,J=7.20,1 .48Hz, 1 H),8.47(d,J=9.5Hz, I 8.41 (dd,J=8. 19,1.46Hz, 1 8. 1 0(dd,J=7. 14,1.24Hz, 1 7.93(d,J=9.63Hz, 1 H), 7.85(t,J=8. 14Hz, 1 7.46(d,J=7.99Hz, 1 4.08(s,3H), 3.7 1 (q,J=5.56Hz,2H), 2.63(t,J=5.95Hz,2H), 2.34(s,6H) 4 C21HF20N402. M+ @360 DMSO; 2.91(6H,s), 3.45(2H,t), 3.97-4.02(2H,m), 7.37(1H,d), 7.72-7.78(1H,m), HBr 7.92(1 8.08-8.12(1 8.45-8.51 8.54-8.61 9.42(1 10. 13(1 H,t), 10.67(1 H,s).
7 C21H19N503 DCJ+NH3, (CDCL3), 2.50( 6H, s, 2xCH3), 2.75( 2H, t, CH2), 3.95( 2H, q, CH2), 7.95( 1 H, t, MH+,390 ArH), 8. 10( 1 H, t, ArH), 8.30( 1 H, d, ArH), 8.45( 1 H, d, ArH), 8.50( 1IH, d, ArH), 8.70( 1 H, ArH), 9. 10( 1IH, dd, ArH), 9.90( 1IH, d, ArH), 10.50( 1IH, Br. NH-).
C22H2lIBrN4 MH+ (Chloroform): 1 0.73(br.t., 1H),8.92(dd, 1H),8.55(t, 1H),8.38(dd, 1H),8.04- 02 453/45 5 7.90(m,3H) 10(d, 1H),4.09(s,3H),3.85(g,2H),2.74(t,2H),2.33(s,6H) 11 C23H2 1N502 MS CDCl3; 2.36(6H,s), 2.68(2H,t,J=5.9Hz), 3.81 -3.84(2H,m), 5.02(2H,s), 7.30(1 H,d=8. 1Hz), DCI/NH-3 7.71-7.75(1 7.92-7.98(2H,m), 8.36-8.41 8.96(1 H,dd,J=7.2, m/e 400 9.15(1 H,d,J=8.3Hz), 10.70(1 H,broad).
100%) 12 C28H26N402 MIS CDC13; 2.42(6H,s), 2.75(2H,t,J=6.OHz), 3.89-3.93(2H,m), 5.35(2H,s), 7.33-7.49(4H,m), DCJI/NH3 7.55(2H,d,J=7.2Hz), 7.73-7.77(1 7.95-8.0(2H,m), 8.40(1 H,dd,J=8.6, m/e 451 8.63(1 H,d,J=9.4Hz), 9.00-9.07(2H,m), 1 0.90(1H,broad).
100%) 13 C24H22N402 MIS CDC13; 2.37(6H,s), 2.55(IH,t,J=2.4Hz), 2.70(2H,t,J=6.OHz), 3.82-3.87(2H,m), DCI/NH-3 4.95(2H,d,J=2.4Hz), 7.32(1 H,d,J=8.3Hz), 7.70-7.74(1 7.90-7.95(2H,m), mle 399 8.35(lIH,dd,J=8.50, 1.6Hz), 8.50(lIH,d,J=9.8Hz), 8.95(l1H,dd,J=7.30, 100%) .9.01(1 H,d,J=8.2Hz), 10.80(1 H,broad).
C23H24N402 MIS jd6-DMSO; I .52(3H,t,J=6.9Hz), 2.35(6H,s), 2.65(2H,t,J=5.9Hz), 3.72-3.75(2H,m), DCIINH3 4.30(2H,q,J=6.9Hz), 7.43(1 H,d,J=7.9Hz), 7.80-7.84(1 H,rn), 7.92(1 H,d,J=9.5Hz), 8.05rn/e 389 8. 10(1 8.42(1 H,dd,i=8.6, 1.6Hz), 8.45(1 H,d,J=9.5Hz), 8.72(1 H,dd,J=7. 1, 100%) 8.94(1 H,d,J=8.2Hz), 10.25(1 16 C25H28N402 El+ m/z 416 CDC13; 10.87 I H, br); 8.93 (2H, in); 8.54 (1IH, d, J 9.5 Hz); 8.35 (1 H, dd, J 8.4, Hz); 7.89 (2H, in); 7.69 (1IH, t, J 8.0 Hz); 7.19 (1 H, in); 3.93 (2H, d, J 6.4 Hz); 3.87 (2H, 346 in); 2.75 (2H, in); 2.40 (6H, 2.24 (1 H, in); 1. 11 (6H, d, J 6.8 Hz).
329 17 C28H25C1N4 DEI in/e d6-DMSO; 2.38(6H,s); 2.62-2.70(2H,in); 3.70-3.77(2H,m); 5.44(2H,s); 02 484/486 3:1 7.52(2H,d,J=8.3Hz); 7.58(1 H,d,J=8.OHz); 7.64(2H,d,J=8.3Hz); 7.88(1 H,t,J=8. 1Hz); 100) 8.01 (1 H,d,J=9.5Hz); 8. 10(1IH,t,J=7.8Hz); 8.46(l1H,d,J=8.4Hz); 8.56(1 8.73(1 H,d,J=7.OHz); 9.03(1 H,d,J=8.OHz); 10.22-1 0.30(lIH,broad peak).
18 C24H26N403 DCI N1-3 CDCI3;2.69(6H,s); 2.92-3.10(2H,m); 3.49(3H,s); 3.83-3.93(2H,t,J=4.4Hz); 3.94-4.10(2H,m); i/e 4.28-4.40(2H,t,J=4.4Hz); 7.22(1 H,d,J=8.OHz); 7.80(1 7.84-7.96(2H,m,J=4.7Hz,8.3Hz); 41 100) 8.37 (1 H,d,J=8.2Hz); 8.54(1 H,d,J=9.4Hz); 8.82(1H,d,J=7.4Hz); 8.90(1 H,d,J=6.9Hz); 11. 10(1 H,broad peak).
21 C23H24N403 CI+ (NH3) CDC13; 10.69 (1H, br); 8.93 (1H, dd, J 1.5 Hz); 8.80 (1H,d, J =8.3 Hz); 8.47 (1H, d, mlz 405 J 9.6 Hz); 8.32 (1 H, dd, J 1.5 Hz); 7.91 (1 H, in); 7.8 5 (1 H, d, J 9.6 Hz); 7.5 7 (1 H, 100%) t, J 8.1 Hz); 7.11 (1IH, d, J =7.9 Hz); 4.27 (2H, in); 4.11 (2H, in); 3.83(2H, q, J 5.7 Hz); 2.68 (2H, t, J =6.0 Hz); 2.35(6H, s).
22 C25H22N602 DCL/NH3 CDC13; 2.40(6H,s), 2.72(2H,t,J=5.9OHz), 3.85-3.89(2H,m), 7.05(1H,t,J=4.8OHz), in/z 439 7.63(1 H,d,J=7.75Hz), 7.80-7.95(3H,in), 8.18(1 H,d,J=9.5Hz), 8.36(1 H,dd,J=8.4, 1.4Hz), 100%) 8.55(2H,d,J=4.8OHz), 9.00(1 H,dd,J=7.2, 1.3Hz), 9.40(1 H,d,J=8. 1 Hz), 10.70(1 H,broad).
23 C27H31N503 DCI/N-3 CDC13; 2.45(6H,s), 2.68-2.71(4H,m), 2.75(2H,t,J=6.OHz), 3.01(2H,t,J=5.6Hz), 3.75in/z 474 3.79(4H,m), 3.88-3.92(2H,m), 4.36(2H,t, J=5.6Hz), 7.25-7.27(1 7.71-7.75(1 H,in), 100%) 7.95-8.01 (2H,in), 8.41 (1 H,dd,J=8.5, 1.5Hz), 8.55(1 H,d,J=9.5Hz), 9.01 -9.05(2H,m), 10.8(1H,broad).
24 C25H25N502 DCJINH3 CDC13; 2.35-2.38(2H,in), 2.45(6H,s), 2.73-2.75(4H, in), 3.89-3.93(2H,in), in/z 428 4.37(2H,J=5.7Hz), 7.28-7.30(1 H,in), 7.78-7.80(1 H,in), 7.98-8.01 (2H,in), 8.45(1 H,dd, J=8.4, 100%) 1.5Hz), 8.56(1 H,d,J=9.7Hz), 9.05(1 H,dd,J=7.2, 1.5Hz), 9.08(1 H, d,J=8.2Hz), 10.8(1 H, broad).
C22H22N40 [M (CDCI3) 10.88 (1 H, br, 9.34 (1iH, d, J 9.02 (1IH, dd, J 7.3, 8.42 (1 H, dd, J 84 0* 4*
S
C S 95555 C S S S S
S
359 8.3 1 (1IH, d, J 8.02 (1 H, d, J 7.98 (1IH, d, J 7.73 (1 H, t, J 7.69 (1 H, 3.91 (2H, g, J 2.75 (3H, 2.60 (2H, t, J 2.44 (6H, s) 26 C2IH19FN4O [M (CDCI3) 10.67 (1IH, s, br), 9.22 (1IH, d, J 8.97 (1IH, dd, J 7.3, 8.36 (1 H, dd, J 8.4, 363 8.29 (1 H, d, J 7.97 (1 H, d, J 7.93 (1 H, dd, J 8. 5, 7.71 (1 H, in), 7.47 (1 H, in), 3.83 (2H, g, J 2.68 (2H, t, J 2.37 (6H, s), 27 C26H3l1N502 DCINHi3 CDCI3; 2.15-2.21 2.34(6H,s), 2.44(6H,s), 2.63(2H,t,J=7.2Hz), 2.79(2H,t,J=6.OHz), m/z 446 3.90-3.95(2H,in), 4.30(2H,t, J=6.3Hz), 7.25-7.27(1 7.71-7.74(1 H,in), 7.95- 100%) 8.01 8.40(1 H,dd,J=8.40, 1.5Hz), 8.55(1 H,d,J=9.5Hz), 8.99-9.03(2H,m), 10.89(1 H,broad).
28 C22H22N40S EI+ m/z 390 CDCl13; 10. 79 (1IH, br); 9.32 (1 H, mn); 9.02 (1 H, dd, J 7.2, 1.5 Hz); 8.63 (1 H, d, J 9.7 Hz); 8.42 (1 H, dd, J 8.4, 1.5 Hz); 8.05 (1IH, d, J 9.7 Hz); 7.99 (1 H, in); 7.76 (2H, in); 3.90 320 (2H, in); 2.75 (2H, mn); 2.66 (3H, 2.43 (6H,s) 29 C23H23N503 DCIJNH3 CDCI3 and two drops of D4-MeOH m/z 2.32(6H,s), 2.68(2H,t,J=6.2Hz), 3.78(2H,t,J=6.2Hz), 4.68(2H,s), 7.20(1H,d,J=7.8Hz), 7.70- 41 8(MH+, 7.72(1 H,in), 7.90-7.95(2H,m), 8.35(1 H,dd,J=1 8.5Hz), 8.53(1 H,d,J=9.8Hz), 100%) 8.86(l1H,dd,J=7.2, 1.5Hz), 8.95(lIH, d, J=8.3Hz).
3 exchangeable protons not visible due to presence of methanol (d4).
C21H20N403 DCIINH3 CDCl3; 2.81(1H,dd,J=12.6, 7.5Hz), 2.97(IH,dd,J=12.6, 3.7Hz), 3.70-3.75(IH,m), 3.90m/z 377 4.00(2H,m), 4.01(3H,s), 7.15(1H,d,J=8.OHz), 7.65-7.71(1H,m), 7.81(1H,d,J=9.5Hz), 7.85- 100%) 7.90(l 8.3 1(1 H,d,J=7.5Hz), 8.42(1 H,d,J=9.6Hz), 8.80(1 H,d,J=8.2Hz), 8.88(IH,d,J=6.lHz), I 1.2(1H,broad).
OH and N1-2 not visible in NMR 31 C23H24N402 DCI+ NH3 DMSO; 1.92(2H,t,J=7.O3Hz), 2.2(6H,s), 2.48(2H,t,J= Hz), 3.62(2H,q,J=6.74Hz), 389 4.07(3H,s), 7.3(1 H,d,J=8.O3Hz), 7.85(1 H,t,J=8.06), 7.98(IH,d,J=9.48), 8.05(1 H,t,J=7.25Hz), 8.42(1 H,d,J=8.64Hz), 8.49(1 H,d,J=9.6Hz), 8.52(1 H,d,J=6.9Hz), 8.72(1 H,d,J=8 .06Hz), 9.95(1 H,broad) 32 C2IH19BrN4 CI+ in/z CDCI3; 10.61 (1IH, br); 9.41 (1IH, d, J 8.0 Hz); 8.97 (1 H, dd, J 7.3, 1.6 Hz); 8.47 (1 H, d, J 0 423:425 9.8 Hz); 8.36 (1IH, dd, J 8.4, 1.5 Hz); 8.02 (2H, in); 7.94 (1IH, in); 7.61 (1IH, t, J 7.9 MH+, 98%) Hz); 3.84 (2H, in); 2.69 (2H, br t, J 5.9 Hz); 2.37 (6H, s).
33 C23H22N403 in/z 403 d6-DMSO: 2.37(6H, 2.52(3H, 2.65(2H, t, 3.72(2H, q, 7.74(l1H, d, 7.99(l1H, t, 8.08(l1H, d, 8.12(l1H, t, 8.3 1(1IH, d, J=9.6), d, 8.75(IH, d, 9.38(IH, d, b* e 'a a. *6 S Cd ell: C. *4 34 C24H24N403 MS CDC13; 2.42(6H,s), 2.45(3H,s), 2.75(2H,t,J=5.9Hz), 3.88-3.91 4.83(2H,s), DCL/NH3 7.1 2(l H,d,J=7.8Hz), 7.71-7.76(1 7.95-8.02(2H,m), 8.45(1 H,d,J=8.4, 1.4Hz), m/z 417 8.63(1 H,d,J=9.6Hz), 9.03(1 H,dd,J=7.2, 1.6Hz), 9.15(1 H,d,J=8. 1 Hz), 10.80(1 H,broad).
100%) C23H24N402 DCINH3 CDC13; 1 .53(3H,d,J=6.5Hz), 2.37(6H,s), 2.55(1 H,dd,J=1 2.2, 6.2Hz), 2.84(1 H,dd,J=1 2.2, m/z 389 7.8Hz), 4.1 0(3H,s), 4.55-4.65(1 7.28-7.30(1 7.75-7.80(1 7.95-8.02(2H,m), 8.42(1 H,dd,J=8.4, 1.5Hz), 8.57( IH,d,J=9.5Hz), 8.81(1 h,d,J=8.2Hz), 9.02(1 H,dd,J=7.3, 100%) 1.6Hz), 10.9(1H,d,J=7.2Hz).
36 C22H19N50 MH+ at 370 DMS0; 9.99(t, IH), 9.62(d,1IH), 8.74(dd,1IH), 8.41 8.3 5(d,1IH), 8.24(d,1IH), 8. 8.00 3.72(g,2H), 2.62(t,2H), 2.35(s,6H).
37 C24H25N503 DCI+ NH3 d6-DMSO; 0.9(3H,t,J=7.4Hz), 2.4(6H,s), 2.75(2H,broad), 3.37(2H,t,J=6.42Hz), 432(MH+) 5.3(2H,broad), 7.57(1 H,d, J=7.2 1Hz) 7.75(1 H,t,J=7.4Hz), 7.91 (2H,t,J=7. 14Hz), 8.13(1 H,d,J=9.58Hz), 8.3( IH,d,J=8.43Hz), 8.95(1 H,d,J=6.72Hz), 9.21(1 H,d,J=7.64Hz), 10.76(1H,broad) One NH not visible 39 C22H22N403 CI+ (Nl-3) d6-DMSO; 9.79 (1H,brmi); 9.64 (IH,d, J =8.0 Hz); 9.10 (IH, d, J =9.8 Hz); 8.65 (IH, S m/z 423 mn); 8.59 (2H, in); 8.40 (1IH, d, J 9.8 Hz); 8.24 (2H, mn); 4.04 (2H, br 3.57 (3H, 3.53 100%) (2H, hr t, J 6.3 Hz); 2.99 (6H, s).
C21H19C1N4 DCI NH3 CDC13; 2.38 (6H, 2.62-2.70 (2H, t, J=8.OHz); 3.78-3.86 (2H, in, J=5.4, 3.0Hz); 7.69 (1IH, O m/e 379 t, J=8.OHz); 7.72 (1H, d, J=0.9, 6.8Hz); 7.94 (1H, t, J=1.3, 7.2Hz); 8.04 (IH, d, 100) 8.37 (1H, d, J=1.5, 6.9Hz); 8.51 (1H, d, J=9.4Hz); 8.98 (1H, d, J=1.5, 5.6Hz); 9.99 (IH, d, J=8.OHz); 10.60 (1IH, broad peak).
41 C21H19N70 [M (CDCI3); 10.75 (IH, br), 9.30 (1H,d, J8.2), 9.04 (1H,d, J7.3), 8.42 (2H, t, J8.4), 8.00 (2H.
386 t. J 7.85 (1IH, t, J 7.63 (1IH, d, J 3.90 (2H, g, br), 2.76 (2 H, t, br), 2.45 (6H, s) 42 C21H21N50 DCI+N-3, (CDCL3), 2.50( 6H, s, 2xCH3), 2.90( 2H, t, CH2), 3.95( 2H, in, CH2), 7. 10( 1IH, d, ArH) MH+, 360 7.65( 1 H, t, ArH), 7.90( 2H, m. ArH), 8.05( 1 H, d, ArH), 8.35( 1IH, d, ArH), 8.70( 1 H, d, ArH), 8.95 I1H, d, ArH),1 1.0(1IH, hr., NE-) 43 C25H23F3N4 DCIINH3 d6-DMSO; 2.70(6H,s), 3.18(2H,t), 3.89-3.95(2H,in), 5.00(2H,s), 7.42(IH,d, J=8.OHz), 06 in/z 419 7.81 -7.86(1H,m), 8.00(1 H,d,J=8.OHz), 8.08-8. 12(IH,m), 8.46(IH,d,J=7.8Hz), 8.55- 100%) 8.62(2H,in), 8.85(IH,d,J=8.lHz), 10.1(IH,broad). 2- acidic OH not visible 44 C23H23N502 MH+, 402 CDCI3), 2.35( 6H, s, 2xCH3), 2.40( 3h, s, CHA) 2.65( 2H, t, CH2), 3.80( 2H, q, CH2), 7.45( 1 H, t, ArH), 7.70( 2H, mn, ArH), 7.90( 2H, mn, ArH), 8.20( 1IH, s, NH), 8.25( 1 H, d, 8.70( 1IH, d, ArH), 8.80( 1 H, d, ArH), 10. 10( 1 H, hr., NH) C23H-22N403 rn/z 403 CDCI3; 2.38 (6H4, 2.70 (2H, t, 3.87 (2H, q, 4.03 (3H, s),7.81 (ILH, t, 7.96 (1 H, t, 8.07 (1 H, d, 8.35-8.40 (2H, in); 9.00 (1 H, d, 9.13 (ILH, d, 9.68 (1iH, d, J=8. 10.65 (1 H, br) 46 C23H25N505 DCI+NH3,M (CDCL3), 2.45( 6H, s, 2xCH3), 2.75( 2H, t, CR2), 3.60( 6H, s, 2xCH3), 3.90( 2H, q, CR2), S2 H+516 7.85(lIH, d, 7.95( 1iH, t, ArH), 8.05( 1IH, t, ArH), 8.20( 1 H, d, ArH), 8.35(l1H, d, ArH), 8.45(1H, d, ArH), 9.08( IH, d, ArH), 9.75( IH, d, ArH), 10.65( IH, br. Ni-).
48 C22H22N602 MH+ 403 d6-DMSO; 2.33(6H,s), 2.63(2H,t,J=5.9lHz), 3.69-3.78(2H,m), 6.16(1H,s), 7.8(IH,broads), 7.93-8. 12(4H,m), 8.22(1 H,broads), 8.42-8.49(1 8.58 (1 H,d,J=1 1.82Hz), 8.72(1 H,d,J=7.22Hz), 9.48-9.52(1 10. 16-10.25(1 H,broadm) 49 C22H22N402 CI+ m/z 375 CDC13; 10.64 (IH, br); 8.92 (1H, dd, J 1.5 Hz); 8.80 (iR,dd, J 1.5 Hz); 8.24 100%) (214, in); 7.86 (1IH, in); 7.69 (3H, in); 5.09 (2H, 3.83 (2H4, in); 2.85 (2H, br in); 2.50 (6H, br s) C24H21F3N4 mlz 389 d6-DMSO): 2.94 (6H, d, 3.49 (2H, in), 4.00 (2H, q, 8.05 (1iH, t, J=7.9), 8.12-8.22 (2H, in), 8.48-8.58 in), 9.17 (1iH, d, 9.4 1(1 H, d, 9.82 (1iH, t) 51 C24H24F3N5 DCIJNi-3 CDCl3/d4-MeOD m/z 2.67(3H,s), 3.05(6H,s), 3.62(2H,t), 4.25(2H,t), 8.00-8.10(3H,in), 8.45-8.50(2H,in), 438(MH+), 8.88(1H,d), 8.99(IH,d), 9.35(IH,d). 2N1- not visible due to presence of MeOD 100% 54 C23H25N50 DCI+NH3, (CDCL3), 2.40( 6H, s, 2xCH3), 2.70( 2H, t, CR-2), 2.90( 6H, s, 2xCH3), 3.85( 2H, q, CR2), MH+ 388 7.40( 1iH, d, ArH), 7.70( 1 H, t, ArH), 7.90( 2H, dd, ArH), 8.40( 1IH, dd, ArH), 8.53( 1IH, d, ArH), 8.95( IH, dd, ArH), 9.10( IH, d, ArH), 10.85( IH, br. NH) C22H23N503 m/z 438 (d4-MeOH)d 8.98 (1iH), 8.79 (1iH), 8.65 (1 8.42 (1IH), 8.09 (1iH), 8.02-7.92 (3H, mn), 4.22 (2H, 3.70 (2H, 3.24 (3H, 3.18 (6H, s) 2NH- not visible 57 C23H25N503 DCI+ NH-3 CDC13; 2.42(6H,s), 2.73(2H,t,J=5.69Hz), 2.89(6H,s), 3.85-3.92(2H,m), S MH+ (452) 7.91(1 H,t,J=7.9 1Hz), 8.02(1 H,t,J=7.34Hz), 8.16(1 H,d,J=9.83Hz), 8.41-8.51 (2H,in), 9.05(1 H,d,J=5.56Hz), 9.09(1I,d,J=9.84Hz), 9.85(1 H,d,J=8. 1Hz), 10.54(1 H,broad) 59 C23H22N60 DCI+NH3, CDCL3), 2.45 6H, s, 2xCH3), 2.80( 2H, t, CR2), 3.10( 2H, s, CR2), 3.90( 2H, q, CR2), MNH4+, 416 7.03( 1 H, d, ArH), 7.75( 1IH, t, ArH), 7.95( 2H, in, ArH), 8.12( 1IH, d, ArH), 8.40( 1iH, d, ArH), 8.80( IR, d, ArH), 9.05( 1H, d, ArH), 10.95( IH.br., NE). One NH not visible C23H24N403 DCIINH3 400MHz, CDCI3. 2.25(6H,s), 2.80(2H,t,J=6.lIHz), 3.82-3.87(2H,in), 4.06(3H,s), m/z 405 4.1 0(3H,s), 6.78(1 H,broad), 7.19(1 H,d,J=7.7Hz), 7.63-7.70(2H,m), 7.85(1 100%) 8.28(1 H,d,J=9.4Hz), 8.45(1 H,d,J=9.4Hz), 8.95(1 H,d,J=8.2 Hz).
61 C23H24N402 DCI+NH3, CDCI3; 10.76(1H,br 8.97 (2H,mi);8.52 (IH,mi);8.40 7.95 7.75 MH+ 389 (1IH,m); 7.23 (1 H,in); 4.05 3.93 (1 H,m) 3.70 (1lH,m); 3.08 (1lH,m); 2.45 (6H, s) 1. 18(3H,d 62 C24H22F3N5 mlz 388 (d6-MeOH): 3.19 (6H, 3.71l(2H, t, 4.25 (2H, t, 8.01-8.16 (4H, in), 8.51 04 (1H, dd, J=8.7 and 8.65 (1H, d, 8.82 (IR, dd, J=6.9 and 9.27 (IH, d, 3 Ni- not visible C24H26N402 MH+ at 403 (d6-DMSO): 9.67(br,IH), 8.95(d,IH), 8.56(d,IH), 8.50(d,1H), 8.43(d,1H), 8.07(m,IH), (100%) 7.98(d, IH), 7.86(m, IH), 7.48(d, IH), 4.07(s,3H), 2.78(s,2H), 2.30(s,6H), 1.56(s,6H).
67 C23H24N402 DCI/NH3 CDC13, 400MHz. 2.42(6H,s), 2.76(2H,t,J=6.OHz), 3.00(3H,s), 3.88-3.92(2H,m), mlz 389 4.1 0(3H,s), 7.30( IH,d), 7.75-7.79(1 H,in), 7.82(IH,d,J=9.4Hz), 8.03(lH,d,J=9.7Hz), 100%) 8.5 5(1 H,d,J=9.7Hz), 8.90(1 H,d,J=7.4Hz), 9.03(1 H,d,J=8.OHz), 10.95(1 H,broad).
68 C21H20N403 DCIIN-3 400MHz, d6-DMSO in/z 377 2.33(6H,s), 2.67(2H,t,J=5.7Hz), 3.75-3.80(2H,m), 7.32(1 H,d,J=7.3Hz), 7.64(1 H,d,J=9.4Hz), 10 7.70-7.74(1 H,in), 7.85(1 H,d,J=9.4Hz), 8.3(1 H,d,J=9.4Hz), 8.40(1 H,d,J=9.4Hz), 8.78(1 H,d,J=8. 1Hz), 10.55(1 H,broad), 11.4(1 H,broad).
one exchangeable proton not visible 71 C24H26N402 in/z 403 (400 MHz, CDCI3): 1.11 (3H, t, 1.78-1.89 (1IR, in), 1.98-2.08 (1IH, in), 2.36 (6H, s, NMe2), 2.59 (1H, dd, J=12.5 and 2.82 (IH, dd, J=12.5 and 4.10 (3H, s, OMe), 4.46-4.54 (1iH, m, 7.27 (1 H, d, 7.76 (1IH, t, 7.94-8.01(2H, in), 8.41 (I H, d, 8.5 7 (1IH, d, 8.79 (1 H, d, 9.01 (1IH, d, 10.92 (1 H, d,
NH)
72 C24H26N403 DCIN-3 400MHz, CDC13 i/e 1.55(3H,d,J=6.4Hz), 2.31(6H,s), 2.39(l1H,dd,J=1 2.2, 6.3Hz), 2.6 1(1 H,dd,J= 12.2, 8.6Hz), 41 9(MH+, 4.07(3H,s), 4.1 0(3H,s), 4.40-4.50(1 H,in), 6.5 1(1 H,broad d,J=6. I1Hz), 7.20(1 H,d,J=7.7Hz), 100%) 7.65-7.71 (2H,in), 7.88(1 H,d,J=9.6Hz), 8.28(1 H,dJ=9.6Hz), 8.45(1 H,d,J=9.7Hz), 8.98(1 H,d,J=8.OHz).
73 C22H21C1N4 DCJ/N-3 400MHz, CDC13 02 ni/e 411/409 2.42(6H,s), 2.75(2H,t,J=5.9Hz), 3.86-3.90(2H,in), 4.08(3H,s), 7.25(1H,d,J=7.8Hz), 7.72- 7.77(1 7.89(1 H,d,J=9.3Hz), 8.36(1 H,d,J=2.5Hz), 8.56(1 H,d,J=9.6Hz), 30,100%) 8.92(1 H,d,J=2.5Hz), 8.95(l H,d,J=8. I1Hz), 1 0.75(l1H,broad).
74 C25H28N402 [M (400 MHz, CDC13) 10.90 (1IH, d, br), 8.95 (1 H, dd, J. 7.3, 8.71 (1 H, d, J 8.48 (11-H, 417 d, J 8.3 3 (1IH, dd, J 8.6, 7.90 (2H, in), 7.68 (1 H, t, J 7.18 (1IH, d, 4.49 (IH, in), 4.01 (3H, 2.83 (1 H, dd, J 12.6, 2.59 (1IH, dd, J 12.6, 2.28 (6H, 2.16 (I H, in), 1. 04 (3 H, d, J 1.03 (3 H, d, J 2.6) C23H24N403 DCI+ NH3, CDC13: 11.05, (lH, d) 8.91, (1H, dd, J=1.47Hz, 7.29Hz) 8.85, (1H, d, J=8.7Hz) 8.50, (IR, MH+ at 405 d, J=9.55Hz) 8.35, (1IH, dd, J=1.48, 8.47) 7.88, (2H, in) 7.71, (1iH, t, J=8.14) 7.20 (1IR, s) 4.55, (1IH, in) 4.05 (5H, in) 2.87, (2H, in) 2.35, (6H, One exchangeable proton not visible.
76 C29H28N402 [M H (400 MHz, CDC 13) 11. 0 (1IH, d, br), 9.02 (1IH, dd, J 7.2, 8.5 5 (1 H, d, J 8.42 (1IH, 465 dd, 8.5, 8.24 (1 H, d, J 7.99 (1 H, d, J 7.96 (1IH, t, J 7.5 5 (1 H, t, J 8. 1), 7.32 (2H, d, J 7.22 (1iH, d, J 7.16 (2H, t, J 7.04 (1 H, t, J 4.83 (1 H, in), 4.09 (3H, 3.27 (1IH, dd, J 13.7, 3.21 (1IH, dd, J 13.7, 2.76 (1 H, dd, J 12.4, 8.3), (1H, dd, J 12.5, 2.31 (6H, s) 77 C23H24N402 DCIIN-3 400MHz, CDC13 in/z 389 1 .53(3H,d,J=6.5Hz), 2.37(6H,s), 2.55(1H,dd,J=1 2.2, 6.2Hz), 2.84(1 H,dd,J=1 2.2, 7.8Hz), 100%) 4.1 0(3H,s), 4.55-4.65(1 H,in), 7.28-7.30(1H,m), 7.75-7.80(1H,n), 7.95-8.02(2H,in), 8.42(1 H,dd,J=8.4, 1.5Hz), 8.5 7(1 H,d,J=9.SHz), 8.81(1 h,d,J=8.2Hz), 9.02(1 H,dd,J=7.3, 1.6Hz), 10.9(1 H,d,J=7.2Hz).
78 C23H24N402 in/z 389 (400 MHz, CDCl3): 1.53 (3H, d, J=6.5, Me), 2.3 8 6H, s, N-Me2), 2.51-2.60 (1IH, in), 2.82- 2.90 (1IH, in), 4.11 (3H, s, MeG), 4.56-4.65 (1IH, in, CH), 7.29 (1 H, d, 7.78 (1 H, t, 7.96-8.02 (2H, in), 8.43 (1 H, d, 8.5 8 (1 H, d, 8.82 (1 H, d, 9.03 (I H, d, J=7.3) 79 C22H21N503 DCI+N-3, 400MHz(CDCL3), 1.50( 3H, 2.35( 6H, 2.55( 1 H, dd), 2.80(lIH,dd), 4.60( 1 H, in), MH+,404 7.90( 1 H, 8. 10( 1IH,t,, 8.25( 1 H, 8.45( 2H, 8.70( 1 H, 9.05( I H,dd), 9.65( 1 10.45(lIH, d, NH).
81 C23H24N403 DC I+ iz 400MHz in CDC13 405 10.97 (1IH, br); 8.91 (1 H, dd, J 7.2 1.5 Hz); 8.76 (1 H, d, J 8.2 Hz); 8.41 (1 H, d, J 100%) Hz); 8.35 (1 H, dd, J 8.6 1.5 Hz); 7.90 (1 H, in); 7.86 (1IH, d, J 9.5 Hz); 7.72 (1 H, t, J Hz); 7.21 (1 H, d, J 8.0 Hz); 5.32 (1lH, br); 4.63 (1 H, in); 4.17 (2H, in); 4.06 (3H, s); 2.96 (1 H, dd, J 12.4 6.0 Hz); 2.88 (1 H, dd, J 12.4 7.4 Hz); 2.39 (6H, s).
82 C23H25N502 MH+ at 404 CDC13: 11.92, (1 H, in) 11. 12, (1IH, in) 8.80, (1 H, d, J=8.33Hz) 8.40, (1IH, d, J=9.53Hz) 8.12, I I I (iR, d, J=9.62Hz) 7.90, (1H, d, J=9.45Hz) 7.70, (IH, t, J=8.O9Hz) 7.56, (1H, d, J=9.59Hz) 7.20, (1 H, d, J=7.83Hz) 4.10, (3H, s) 3.83, (2H, q, J=6.6Hz) 3.18, (3H, d, J=5.1 1 Hz) 2.77, 83 C23H24N403 DCIJNH3 400MHz, CDC13 MH+ 405 1.52(3H,d,J=6.6Hz), 2.37(6H,s), 2.56(IH,dd,J=1 2.4, 6.0Hz), 2.85(IH,dd,J=12.4, 8.1Hz), (100%) 4.1 0(3H,s), 4.52-4.62(1 7.25(1 H,d,J=7.8Hz), 7.57(1 H,d,J=9.4Hz), 7.75-7.78(1 H,m), 7.96(1 H,d,J=9.5HZ), 8.2 1(1 H,d,J=9.4Hz), 8.49(1 H,d,J=9.3Hz), 8.68(1 H,d,J=9.2Hz), H,d,broad), 16.2(1 H,s).
84 C24H26N403 m/z CI+ 419 400MHz in CDC13 11.21 (1IH, br); 9.27 (1 H, d, J 8.2 Hz); 9.02 (1 H, dd, J 7.3 1.5 Hz); 8.53 (1H, d, J 9.6 Hz); 8.42 (IH, dd, J 8.6 &1.5 Hz); 7.99-7.91 (2H, in); 7.75 100%); 305 (1 H, t, J 8.2 Hz); 7.35 (1IH, d, J 8.0 Hz); 4.43 (2H, mn); 4.06 (3H, 3.48 (1IH, 3.06 (1 H, dd, J 13.1 5.2 Hz); 2.88 (1IH, dd, J 13.1 4.8 Hz); 2.36 (6H, 1.37 (3H, d, J Hz).
C22H22N403 DCI/N113 400MHz, CDC13 2.42(6H,s), 2. 78(2H,t,J=6.OHz), 3.86-3 .90(2H,m), 4.1 0(3H,s), MH+39 1 7.25(1 H,d,J=7.8Hz), 7.57( 1H,d,J=9.4Hz), 7.70-7.75(1 H,in), 7.95(1H,d,J=9.4Hz), 8.22(1 H,d,J=9.4Hz), 8.51(1 H,d,J=9.6HzO, 8.81(1 H,d,J=8.2Hz), 11.65(1 H,br), 16.17(1 H,s).
86 C25H26N402 DCI NH3 400MHz, CDC13 mle 414.4 1.35(2H,in), 1.45(4H,in), 2.47(4H,in), 2.7(2H,t), 3.7(2H,m), 4.07(3H,s), 7.5(1H,d) (MH+,100%) 7.83(IH,in), 7.95(1H,d), 8.07(IH,in), 8.43(1H,in), 8.5(1H,in), 8.62(IH,in), 8.73(1H,m), broad) 87 C24H26N403 [M (400 MHz, CDC13) 11.05 (1 H, 8.92 (1IH, dd, J 7.2, 8.53 (1 H, d, J 8.48 (1IH, d, J 419 8.35 (1IH, dd, J 8.5, 7.94-7.86 (2H, in), 7.69 (1 H, t, J 7.19 (1 H, d, J 4.59 (I1H, q, J 4.02 (3H, 3.80-3.67 (2H, in), 3.44 (1 H, dd, J 12.2, 2.63 (1 H, dd, J 12.2, 2.1) 2.35 (6H, 2. 10 (1IH, in), 1.99 (1 H, in). One exchangeable proton not visible 88 C22H23N502 MH+ at 390 CDC13 11.75, (in, IH) 8.80, 1H, J=8.24Hz), 8.43, (IH, J=9.29Hz) 8.01, IH, J=9.32Hz) 7.9 1, I1H, J=9.48Hz) 7.72, I H, J=8. IOHz) 7.23, I1H, J=9.34Hz) 7.20, (d, I1H, J=7.74Hz) 4.09, 3H) 3.87, 2H, J=6.10) 2.70, 2H J=6.43Hz) 2.42, 6H). NH2 visible.
89 C24H24N403 DCI/NH3 400MHz, CDC13 in/e 417.2 2.62(4H,t), 2.9(2H,t), 3.65(4H,t), 3.93(2H,m), 4.20(3H,s), 7.25(l1H,m), 7.7(lIH,t), 8.00(2 mi), 8.45(1 H,in), 8.60(1 8,75(l 9.0(1 10.9(1 H,broad) C24H24N402 IDCIJNH3 1400MHz,CDCl3 t S. C.
C
rn/e 401 1.82(4H,t), 2.75(4H,t), 3.2(2H,t), 3.90-3.99(2H,rn), 4.1 1(3H,3), 7.26-7.3 1(1 7.78(l H,t), 7.95-7.98(1 H,rn), 7.98-8.03(1 H,rn) 8.4-8.46(1 8.55-8.61 (1 H,rn), 8.78-8.83(1 H,rn), 8.98-9.3(1 H,m) NH not visible 91 C24H26N404 DCL'NH3 400MHz, CDC13 rn/c 435.3 2.75(4H,t), 3.00(2H,t), 3.56(4H,t), 3.80-3.89(2H,rn), 4.40(3H,s), 7.16-7.22(1H,rn), 7.69- 7.75(1 H,rn), 7.85-7.89(1 H,rn), 7.89-7.93(IH,rn), 8.33-8.39(IH,rn), 8.47-8.5 1(1H,rn), 8.51- 8.89-8.95(lIH,rn), 1 1.29(lIH,broad). 2xOH not visible 92 C24H26N402 DCIJNH3 400MHz,DMSO mle 403.3 0.99(6H,t), 2.65(4H,q), 2.79(2H,t), 3.65-3.72(2H,rn), 4.07(3H,s), 7.49-7.53(1H,rn), 7.8- 7.87(IH,m), 7.98(1 8.04-8.1 1(1H,rn), 8.45(1H,rn), 8.51(1 8.67(1 H,rn), 8.89(1 10. 15-10.25(1 H,broad).
93 C23H24N402 ESI +ve rn/c 400MHz, CDC13 S 421 2.42(6H,s), 2.70(3H,s), 2.75(2H,t,J=6.OHz), 3.85-3.90(2H,m), 4.10(3H,s), 100%) 7.24(1 H,d,J=8.OHz), 7.72-7.77(1 H,rn), 7.91(1 H,d,J=9.5Hz), 8.00( 1H,d,J=2.4Hz), 5(1 H,d,J=9.7Hz), 8.85(1 H,d,J=2.4Hz), 8.99(1 H,d,J=8.OHz), 10.85(1 H,broad).
94 C23H24N403 ESI +ve rn/c CDC13, 400MHz 405 2.42(6H,s), 2.75(2H,t,J=6.OHz), 3.85-3.90(2H,m), 4.07(3H,s), 100%) 4.1 0(3H,s),7.22(1 H,d,J=8.OHz), 7.64(1 H,d,J=3.OHz), 7.72-7.77(1 7.9 1(1 H,d,J=9.4Hz), 8.55(1 H,d,J=9.6Hz), 8.70(1 H,d,J=3.OHz), 8.99(1 H,d,J=8.OHz), 1 0.92(IH,broad).
C24H26N404 DCI/N-3 400MHz, CDC13 rn/e 435 2.32(6H,s), 2.65(1H,dd,J=12.3,6.7Hz), 2.75(1H,dd,J=12.3, 8.1Hz), 3.98(IH,dd,J=1 1.3, 4. 1Hz), 4.05(3H,s),4.09(3H,s), I1H under 2 methoxy peaks, 4.41-4.48(l1H,rn), 100%) 6.9 1(1 H,d,J=5.3Hz), 7.20(1 H,d,J=7.9Hz), 7.67-7.71 (2H,rn), 7.86(1 H,d,J=9.6Hz), 8.29(1 H,d,J=9.4Hz), 8.45(1 H,d,J=9.7Hz), 8.91 (1H,d,J=8.2Hz).
one exchangable proton not visible 96 C2l1H20N402 DCIINT3 400MHz, CDC13 rn/c 361.0 2.64(3H,s), 3.1 2(2H,t), 3.90-3.96(2H,m), 4.11 7.29(1 7.63-7.71 (1 7.92- 7.95(IH,rn), 7.95-8.01(1 H,rn), 8.38-8.45(1H,rn), 8.55-8.61(1 H,rn), 8.89-8.95(1H,m), 8.95- I9.02(IH,rn), 1 1.08(1H, broad) 97 C23H24N404TDCIIN-3 400MHz, CDC13 m/z 421 12.40(6H,s), 2.92(l1H,dd,J= 12.4, 7.6Hz), 2.99(lH,dd,J= 12.4, 5.9Hz), 4.07(3H,s), 4.18a. *t
I
a. S a. S.
too a to S *5 5 a S S S S S S 100%) 4.20(2H,m), 4.58-4.68(1 7.21(1 H,d,J=7.9Hz), 7.53(1H,d,J=9.5Hz), 7.70-7.73(1 H,m), 7.86(1 H,d,J=9.4Hz), 8.15(1 H,d,.T=9.4Hz), 8.37(1 H,d,J=9.3Hz), 8.65(1 H,d,J=8.3Hz), 1 1.70(IH,d), 15.82(1H,s) exchangable proton not visible 98 C25H28N402 [M (400 MHz, CDC13) 11.0 (1IH, br, 9.03 (1 H, dd, J 7.3, 8.80 (1 H, d, J 8.56 (1 H, d, 417 J 8.41 (1IH, dd, J 8.5, 7.97 (2H, in), 7.75 (1 H, t, J 7.26 (1 H, d, J 4.56 (I1H, mn), 4.09 (3 H, 2.8 9 (1IH, dd, J 12.6, 2.64 (1 H, dd, J 12.6, 2.3 4 (6H, 2.2 2 (I H, mn), 1. 12 (3 H, d, J 1.10 (3 H, d, J 2.4) 99 C23H22N402 DCIJNH3 CDC13/ 400MHz, ni/z 387 2.02-2.1 0(1H,in), 2.40-2.46(1 H,in), 2.52-2.61(1 2.58(3H,s), 2.75-2.79(1 H,in), 2.99- 100%) 3.02(1 H,in), 3.13-3.18(1 H,in), 4.1 0(3H,s), 4.90-4.98(1 H,in), 7.26(lIH,d), 7.75-7.80(1 H,m), 7.95-8.00(2H,in), 8.42(1 H,dd,J=8.4, 1.5Hz), 8.58(1 H,d, J=9.6Hz), 8.99-9.03(2H,m), 1 1.32(1H,d).
100 C25H29N502 MH+ 432 (400 MHz, CDC13): 2.25 (6H, 2.32-2.38 (1 H, in), 2.52 (6H, 2.56-2.62 (1 H, in), 3.00- 3.09 (1 H, in), 3.65-3.74 (1IH, in), 4.01-4.09 (1 H, in), 4.11 (3H, 7.28 (1IH, d, J 7.78 (1H, t, J8.0), 7.96-8.01 (2H,mi), 8.42 (IH, d, 8.58 (IH, d, 8.98-9.03 (2H, i)

Claims (13)

1. A compound which is a benzo[a]phenazine-l 1-carboxamide derivative of formula (I) N R6 (I) R 1 (1) R N R 7 R R1 O -N(R8)(R 9 H R2 H wherein each ofR' to R 3 is hydrogen and R 4 is selected from halogen, hydroxyl, CI-C 6 alkoxy which is unsubstituted or substituted, heteroaryloxy, CI-C 6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO 2 R 1 0 CON(R12) 2 OCON(R' 2 SR I0 SOR", SO 2 SO 2 N(R 1 2) 2 N(R12) 2 NR'OS0 2 N(SO 2 Rn,) 2 NR'O(CH 2 )nCN, NR'°COR", OCOR" or COR 1 0 each ofR 5 to R 7 which are the same or different, is selected from hydrogen, halogen, hydroxy, CI-C 6 alkoxy, CI-C 6 alkyl, SRI' and N(RI2) 2 Q is CI-C 6 alkylene which is unsubstituted or substituted by Ci-C 6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not cc to either of the N atoms adjacent to Q in formula (iii) CO 2 R 10 or (iv) CON(R' 2 2 8 R 8 and R 9 which are the same or different, are each hydrogen or CI-C 6 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered 15 N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R 8 and R 9 is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated or 6-membered N-containing heterocyclic ring as defined above; R' 1 is hydrogen, CI-C 6 alkyl, C 3 -C 6 cycloalkyl, benzyl or phenyl; 20 R' is Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, benzyl or phenyl; each R 1 which are the same or different, is hydrogen, CI-C 6 alkyl, cycloalkyl, benzyl or 12 phenyl, or the two R groups form, together with the nitrogen atom to which they are attached a 5- or 6-membered saturated N-containing heterocyclic ring which may include 1 or 2 additional heteroatoms selected from O, N and S; and n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein the benzo[a]phenazine-l 1-carboxamide derivative is of formula (Ia): A598140spcci R (1a) N j R 73 R 3 WRI 0 -H(CH 2 H wherein R1 to R9are as defined in claim 1; p is 1, 2 or 3; and R 1 3 is hydrogen, (11) CI-C 6 alkyl which is unsubstituted or substituted by hydroxy, aryl or N(R 12)2 in which R 12 is as defined in claim 1, (iii) CO 2 R' 0 (iv) CON(RI )2 or aryl.
3. A compound according to any one of the preceding claims wherein R 4 IS C 1 -C 6 alkoxy, hydroxy, C 1 -C 6 alkyl, hydroxy-Ci-C 6 alkyl, nitrile or halogen.
4. A compound according to any one of the preceding claims wherein R 7 is hydroxy. A compound as defined in claim 1 which is selected from: 4-Methoxy-benzo[ajphenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-I-lydroxy-benzo[ajphenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-amide: hydrobromide salt 4-Nitro-benzo[a]phenazine- II-carboxylic acid (2-dimethylamino-ethyl)-amide
9-Bromo-4-methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Cyanomethoxy-benzo[a] phenazine- I1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Benzyloxy-benzo[ajphenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Prop-2-ynyloxy-benzo[ajphenazine-l 1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Ethoxy-benzo[alphenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-lsobutoxy-benzo[a]phenazine- I1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-(4-Chloro-benzyloxy)-benzo[alphenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-amide 4-(2-Methoxy-ethoxy)-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-(2-Hiydroxy-ethoxy)-benzo[ajphenazine- I I -carboxylic acid (2-dimethylamino-ethyl)-amide 4-(Pyri mid M-2 -yloxy)-benzo[alphenazi ne- I1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-(2 -Morpholin-4-yl-ethoxy)-benzo[ajphenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)- amide 4-(3 -Cyano-propoxy)-benzo[a]phenazine-I 1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Methyl-benzo[a]pbenazine- I11 -carboxylic acid(2-dimethylamino-ethyl)-amide 4-Fl uoro-benzo[a]phenazine- I I -carboxylic acid(2-dimethylamino-ethyl)-amide A598140speci 4-(3 -Dimethylarnino-propoxy)-benzo[a]phenazine-I 11-carboxylic acid (2-dimethylamino-ethyl)- amide 4-Methylsul fanyl-benzo[a]phenazine-I 1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Carbamoylmethoxy-benzo[a]phenazine-I 11-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine-I I-carboxyl ic acid (3-amino-2-hydroxy-propyl)-amide 4-Methoxy-benzo[a]phenazine-I 1-carboxylic acid (3-dimethylamino-propyl)-amide 4-Bromo-benzo[ajphenazine- I 1-carboxylic acid (2-dimethylamino-ethyl)-amide Acetic acid II -(2-dimethylamino-ethylcarbamoyl)-benzo[ajphenazin-4-y ester 4-(2 -Oxo-propoxy)-benzo[ajphenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine-I I-carboxylic acid (2-dimethylamino-lI-methyl-ethyl)-amide 4-Cyano-benzo[a]phenazine- 11I -carboxylic acid (2-dimethylamino-ethyl)-amide Ethyl-carbamic acid I11 -(2-dimethylamino-ethylcarbamoyl)-benzo[a]phenazin-4-y ester 4-Methanesul fonyl-benzo[a]phenazine- 11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Chloro-benzo[a]phenazine- I1I -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Azido-benzo[a]phenazine-1I I -carboxylic acid(2-dimethylamino-ethyl)-amide 4-Amino-benzo[ajphenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide [I1 -(2-Dimethylamino-ethylcarbamoyl)-benzo[a]phenazin-4-yloxy] -acetic acid tn fluoro-acetate salt 4-Acetylamino-benzo[a]phenazine- I1I -carboxylic acid (2-dimethylamino-ethyl)-amide 1 I -(2-Di methylamino-ethylcarbamoyl )-benzo[ajphenazine-4-carboxyl ic acid methyl ester 4-Bis-(Methanesulfonyl)amino-benzo[alphenazine-I 11-carboxylic acid (2-dimethylamino-ethyl)- amide 4-(N-Hydroxycarbamimidoyl)-benzo[alphenazine- I1I -carboxylic acid (2-dimethylamino-ethyl)- amide *4-Hydroxymethyl-benzo[alphenazine-I 11-carboxylic acid (2 -d imethyl amino -ethyl) -a mide I 1-(2-Dimethylamino-ethylcarbamoyl)-benzo[ajphenazine-4-carboxylic acid, trifluoroacetate salt *4-M ethyl su I famoyl -benzo phenazine- I11 -carboxylic acid (2 -dimethyl amino -ethyl) -a mide; trifluoro-acetate 4-iehlmn-ez*lhnzn- *-abxlcai 2dmtyaioehl-md '4-uMehnsfnylamno-benzo[a]penazne-I 1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Minethnesulfaonylm-benzo~a]phenazine- 1-carboxylic acid (2-dimethylamino-ethyl)-amide 4-Diamethyl amo-benzo[aphenazine- 1-carboxyl ic acid (2-dimethylamino-ethyl)-amide 4,1-(Canmethymo-benzo[a]phenazine- 11-carboxylic acid (2-dimethylamino-ethyl)-amide 4.-imethoxy-benzo[a]phenazine- 1 -carboxylic acid (2-dimethylamino-ehyl)-amide Benzo[ajphenazine-4,1 I-dicarboxyl ic acid 4-amide II -[(2-dimethylamine-ethyl)-amide]; triflouroacetic acid salt A 5S I 4Ospwc 4-Methoxy-benzo[alphenazine- I11 -carboxylic acid (2-d imethyl amino- 1, 1 -d imethyl -ethyl) -a mide 4-Methoxy-8-methyl-benzo[alphenazine-I 1-carboxylic acid (2-dimethylamino-ethyl)-amide 4,1 O-Dihydroxy-benzo[alphenazine-I 11-carboxyl ic acid (2-dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (1 -dimethylaminomethyl-propyl)-amidc 4, 1 O-Dimethoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino- 1 -methyl-ethyl)-amide 9-Chloro-4-methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- I1-carboxylic acid (1 -dimethylaminomethyl-2-methyl-propyl)- amide 4-Methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino- 1 -hydroxymethyl -ethyl)- amide 4-Methoxy-benzo[a]phenazine- 11 -carboxylic acid (1 -dimethylaminomethyl-2-phenyl -ethyl)- amide 4-Methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino- 1 -(S)-methyl -ethyl) -am ide 4-Methoxy-benzo[a]phenazine-I 11-carboxyl ic acid (2-dimethylamino-l1-(R)-methyl-ethyl)-amide 4-Nitro-benzo[a]phenazine-I 11-carboxylic acid (2-dimethylamino-l1-methyl-ethyl)-amide 4-Methoxy-benzo[a] phenazine- I11 -carboxylic acid (2-dimethylamino- I -(S)-hydroxymethyl -ethyl)- amide 4-Mcthoxy- 1 -methylamino-benzo[a]phenazine-I 11-carboxylic acid (2-dimethylamino-ethyl)- am]de I O-Hydroxy-4-methoxy-benzo[alphenazine- I11 -carboxylic acid (2-dimethylamino- 1 (R)-methyl- ethyl)-amide 4-Methoxy-benzo[alphenazine- 11I -carboxylic acid (I -dimethylaminomethyl-2-hydroxy-propyl)- amide I O-Hydroxy-4-methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Methoxy-benzo[a]phenazine- I1I -carboxylic acid (2-piperidin- 1 -yl-ethyl)-amide 4-Methoxy-benzo[alphenazine- I11 -carboxylic acid [1I -dimethylamino- 1 -(2-hydroxyethyljj- ethylamide I O-Amino-4-methoxy-benzo[a]phenazine- I11 -carboxylic acid (2-dimethylamino-ethyl)-amide 4-Mthxybezoajheazne II carboylicaci (2-mompholin-4-vl-cthvl)-amide 4-Methoxy-benzo[a]phenazine- I1I -carboxylic acid (2-pyrrolidin- I -yI-ethyl)-amide 4-Methoxy-benzo[a]phenazine-I 1-carboxylic acid {2-[bis-(2-hydroxy-ethyl)-ami no] -ethyl -amide 4-Methoxy-benzo[ajphenazine-I 1-carboxylic acid (2-diethylamino-ethyl)-amide 4-Methoxy-9-methylsul fanyl -benzo[a]phenazine- 1I -carboxylic acid (2-dimethylamino-ethyl)- amide 4.9-Dimethoxy-benzo[a]phenazine- I1I -carboxylic acid (2-di methylamino-ethyl)-amide 4. 1 0-Dirnethoxy-benzo[a]phenazine- I I -carboxyl ic acid (2-dimethylamino- 1 (S)-hydroxymethyl- A598[140spec 68 ethyl)-amide 4-Methoxy-benzo[a]phenazine- 11-carboxylic acid (2-methylamino-ethyl)-amide
10-Hydroxy-4-methoxy-benzo[a]phenazine- 11-carboxylic acid (2-dimethylamino-l hydroxymethyl-ethyl)-amide (R)-4-Methoxy-benzo[a]phenazine- 1-carboxylic acid(1-dimethylaminomethyl-2-methyl-propyl)- amide 4-Methoxy-benzo[a]phenazine- I -carboxylic acid (l-methyl-pyrrolidin-3-(R)-yl)-amide 4-Methoxy-benzo[a]phenazine- I -carboxylic acid (2,3-(bis)-dimethylamino-propyl) amide and the pharmaceutically acceptable salts thereof. 6. A process for producing a compound as defined in claim 1, which process comprises: treating an activated derivative of a compound of formula (II): R N R 4 (H) R 2 C0 2 H wherein R' to R are as defined in claim 1, with an amine of formula (III): H2N N(R (I) P wherein Q, R 8 and R 9 are as defined in claim 1; or treating a compound of formula (IV): R N R 6 4 R N R7 R R 2 R nl wherein R' to R 7 and R 1 are as defined in claim 1, with a compound of formula (III) as defined above, either in an organic solvent or neat, and at an elevated temperature; and if desired, converting the resulting benzo(a)phenazine-l 1-carboxamide derivative into another such derivative by routine chemical modification, and/or converting a benzo[a]phenazine- 11-carboxamide derivative into a pharmaceutically acceptable salt thereof. A598140spCci 69 7. A process for producing a compound as defined in claim 1, substantially as hereinbefore described with reference to Example 1 or Example 2. 8. A compound of Formula as defined in claim 1, produced by a process according to claim 6 or claim 7. 9. A compound according to claim 1 and specifically as hereinbefore described with reference to Example 1 or Example 2. A compound of formula (II): R N R6 3 RI CO 2 H R 2 wherein R' to R 7 are as defined in claim 1, or a salt or ester thereof.
11. A process for producing a compound of formula (II) as defined in claim 10, which process comprises: treating a 1,2-naphthoquinone of formula O R 4 0 (V) 2 R 2 Swherein R' to R 4 are as defined in claim 1, with a benzoic acid of formula (VI): R H 2 N 6 (VI) H 2 N R 7 CO 2 H or an ester or salt thereof, wherein R 5 R 6 and R 7 are as defined in claim 1, in an organic solvent. AS)9140spcci
12. A process according to claim 11 which is conducted in the presence of from 1 to equivalents of a mineral acid.
13. A process for producing a compound of formula (II) as defined in claim substantially as hereinbefore described with reference to Reference Example 1.
14. A compound of Formula (II) as defined in claim 10, produced by a process according to any one of claims 11 to 13. A compound of Formula (II) as defined in claim 10 and specifically as hereinbefore described with reference to Reference Example 1.
16. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, a compound as defined in any one of claims 1 to 5, 8 or 9.
17. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, a compound of Formula as defined in claim 1, substantially as hereinbefore described with reference to Example 4. 15 18. A compound as defined in any one of claims 1 to 5, 8 or 9 for use in a method of treatment of the human or animal body by therapy. 9. A compound as claimed in claim 8 for use as an inhibitor of topoisomerase
2019. A compound as claimed in claim 18 for use as an inhibitor of topoisomerase I. 21. A compound as claimed in claim 18 for use as a joint inhibitor of topoisomerase I and 20 topoisomerase II. 22. A compound as claimed in any one of claims 18 to 21 for use in the treatment of a tumour. S* 23. A compound as claimed in claim 22 wherein the tumour expresses MDR. 24. A compound according to claim 23 wherein the MDR is P-glycoprotein mediated MDR. A compound according to claim 23 wherein the MDR is MRP mediated MDR. 26. A compound according to claim 23 wherein the MDR is atypical MDR. A59S I 71 27. A compound as claimed in claim 18 for use as an antiviral, antibacterial or antifungal agent. 28. Use of a compound as defined in any one of claims 1 to 5, 8 or 9 for the manufacture of a medicament for use as an inhibitor of topoisomerase I and/or topoisomerase II. 29. Use according to claim 28 wherein the medicament is for oral administration in the treatment of a human or animal bearing a tumour. Use according to claim 28 wherein the medicament is for parenteral administration in the treatment of a human or animal bearing a tumour. 31. Use of a compound as defined in any one of claims 1 to 5, 8 or 9 for the manufacture of a medicament for use as an inhibitor of topoisomerase I and/or topoisomerase II, substantially as hereinbefore described with reference to Example 4. 32. A method of treating a human or animal patient in need of an inhibitor of topoisomerase I and/or topoisomerase II, which method comprises administering to the patient a compound according to any one of claims 1 to 5, 8 or 9, or a pharmaceutical 15 composition according to claim 16 or claim 17. 33. A method according to claim 32 wherein the patient bears a tumour. 34. A method according to claim 32 or claim 33 wherein the compound is administered orally. A method according to claim 32 or claim 33 wherein the compound is administered 20 parenterally. Dated 30 January, 2006 XENOVA LIMITED Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON ASS93O1 spci
AU17184/01A 1999-12-02 2000-12-01 Benzo(A)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II Ceased AU784397B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9928542 1999-12-02
GBGB9928542.1A GB9928542D0 (en) 1999-12-02 1999-12-02 Pharmaceutical compounds
PCT/GB2000/004609 WO2001046157A1 (en) 1999-12-02 2000-12-01 Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase i and ii

Publications (2)

Publication Number Publication Date
AU1718401A AU1718401A (en) 2001-07-03
AU784397B2 true AU784397B2 (en) 2006-03-23

Family

ID=10865607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17184/01A Ceased AU784397B2 (en) 1999-12-02 2000-12-01 Benzo(A)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

Country Status (16)

Country Link
EP (1) EP1240148A1 (en)
JP (1) JP2003518103A (en)
KR (1) KR100767613B1 (en)
CN (1) CN1304380C (en)
AU (1) AU784397B2 (en)
BR (1) BR0016093A (en)
CA (1) CA2392873A1 (en)
GB (2) GB9928542D0 (en)
HK (1) HK1046133B (en)
HU (1) HUP0300392A3 (en)
MX (1) MXPA02005476A (en)
MY (1) MY136029A (en)
PL (1) PL356482A1 (en)
TW (1) TWI280242B (en)
WO (1) WO2001046157A1 (en)
ZA (1) ZA200204296B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2433071A (en) * 2005-12-05 2007-06-13 Kontrakt Technology Ltd Organic acids comprising planar conjugated heterocyclic molecular system, & photoelectric layer thereof with rodlike supramolecules for use in solar cell
CN102898388B (en) * 2012-09-26 2014-12-03 浙江工业大学 Method for synthesizing substituted benzo[alpha]phenazine compound
CN103360329B (en) * 2013-07-18 2015-11-18 中国科学院南海海洋研究所 One class compound phenazine and preparing the application in antitumor drug
CN106554321B (en) * 2015-09-25 2019-05-28 陆源 A kind of azophenlyene substance, preparation method and its application
CN113461623A (en) * 2021-07-14 2021-10-01 长江大学 Antiviral compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024096A2 (en) * 1992-05-28 1993-12-09 Xenova Limited Use of n-(2-(dimethylamino)ethyl)acridine-4-carboxamide and its analogues for cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696131A (en) * 1993-01-22 1997-12-09 Xenova Limited Treatment of cancers
EP0950054A1 (en) * 1996-09-23 1999-10-20 Rutgers, The State University Of New Jersey Substituted heterocycles as anti-tumor agents
WO1998045272A1 (en) * 1997-04-07 1998-10-15 Latrobe University Topoisomerase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024096A2 (en) * 1992-05-28 1993-12-09 Xenova Limited Use of n-(2-(dimethylamino)ethyl)acridine-4-carboxamide and its analogues for cancer treatment

Also Published As

Publication number Publication date
JP2003518103A (en) 2003-06-03
GB2373499A (en) 2002-09-25
ZA200204296B (en) 2003-05-29
GB9928542D0 (en) 2000-02-02
TWI280242B (en) 2007-05-01
KR100767613B1 (en) 2007-10-19
KR20020070305A (en) 2002-09-05
GB0215275D0 (en) 2002-08-14
HUP0300392A2 (en) 2003-07-28
MXPA02005476A (en) 2003-09-22
AU1718401A (en) 2001-07-03
WO2001046157A1 (en) 2001-06-28
EP1240148A1 (en) 2002-09-18
CN1433406A (en) 2003-07-30
CA2392873A1 (en) 2001-06-28
BR0016093A (en) 2002-08-20
HK1046133B (en) 2005-04-15
HUP0300392A3 (en) 2003-09-29
GB2373499B (en) 2004-11-17
HK1046133A1 (en) 2002-12-27
CN1304380C (en) 2007-03-14
PL356482A1 (en) 2004-06-28
MY136029A (en) 2008-07-31

Similar Documents

Publication Publication Date Title
EP2588466B1 (en) 5-Amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (BACE)
US8227480B2 (en) Indazole derivative having spiro ring structure in side chain
US8404738B2 (en) 4-amino-N-hydroxy-benzamides for the treatment of cancer
US20190144499A1 (en) Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof
TW202321252A (en) Novel spiropyrrolidine derived antiviral agents
EP2613775B1 (en) N-hydroxy-benzamides for the treatment of cancer
US20230210847A1 (en) Substituted Alkynylene Compounds As Anticancer Agents
AU784397B2 (en) Benzo(A)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II
WO2023116824A1 (en) Pyridazinone compound and preparation method therefor, pharmaceutical composition thereof, and application thereof
RU2378270C2 (en) Benzyloxy-derivatives as monoamine oxidase b inhibitors
EP2142518B1 (en) 3,4-dihydroquinazoline derivatives
US7132419B2 (en) Pharmaceutical compounds
WO2018098781A1 (en) Pyrrolidinone compounds
KR100820039B1 (en) Alkylamino naphthalenyloxymethyl propenyl hydroxybenzamide derivatives having inhibitory activity against histone deacetylase, method for the preparation thereof, and anticancer composition comprising the same
CN113929674B (en) Compound containing 1, 4-dihydro quinazoline structure, preparation method and application thereof
CN114573567B (en) Indazole cyclotriazole compound and preparation method and application thereof
Shehab et al. Synthesis of some 3-indolyl heterocycles and evaluation of its antimicrobial activity
KR20110048337A (en) 6-Amino-N-hydroxyhexanamide compounds having inhibitory activity against histone deacetylase, and method for preparation thereof
AU2011263836A1 (en) 5-amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (BACE)